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ABSTRACT 
 
 
More than 26 million individuals have submitted to direct-to-consumer genetic 
testing (DTCGT) services since the personal genomics industry gained traction in the late 
2010s. Private firms AncestryDNA and 23andMe dominate the market, and as a result, 
hold ownership of some of the largest collections of human genetic data in the world. As 
a novel technology that analyzes consumer disease risk or genetic genealogy, DTCGT 
has emerged alongside a number of ethical, legal, and social implications that require 
scholarly investigation. This study places a critical eye on AncestryDNA and 23andMe to 
examine how DTCGT is contextualized in the news media. Using a Foucauldian 
discourse analysis, 50 articles from The New York Times, The Wall Street Journal, and 
USA Today were analyzed to capture present discourses and ethical critiques of DTCGT. 
Results of this study cast the genetic testing consumer as self-managing, datafied, and 
valuable. Consumers’ quests to develop their genetic knowledge form the foundation of a 
bioeconomy that private firms and government entities use to advance research and 
innovation while implicitly reiterating neoliberal notions of autonomy, productivity, 
control, and individual responsibility. Issues of third-party sharing of genetic data, 
informed consent, risks and uncertainties about testing, genetic privacy, and more are 
discussed as they are presented in the news media. In light of these critiques, this analysis 
demonstrates a need for regulatory action and scholarly analysis on how DTCGT is 
contextualized as society becomes increasingly datafied and risk-aware.  
Keywords: genetic data, datafication, biopolitics, governmentality, risk, discourse  
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INTRODUCTION 
 
 
The first direct-to-consumer (DTC) genetic tests hit the market in 1996, offering a 
mail-order option outside of a healthcare clinic that could help individuals tailor their diet 
based on genes linked to nutrient metabolism (Bowen and Khoury, 2018; Hogarth and 
Saukko, 2017). The genomics market at the time was small-scale and expensive: few 
diseases had well-known genetic associations, and labor-intensive testing procedures 
translated into tests that cost hundreds, if not thousands, of dollars for the consumer 
(Helgason and Stefánsson, 2010). In the following ten years, technology to discover 
disease variants improved with the emergence of the genome-wide association study 
(GWAS), an observational approach that examines the genomes of many individuals in 
order to associate specific genetic markers with a disease or trait. Under a GWAS, if one 
type of genetic marker is found more frequently in people with a disease, then that 
marker is thought to contribute to disease risk. The GWAS transformed human genetics 
of the early 2000s by allowing millions of genetic variants to be “read” at one time 
through the use of SNP arrays, single nucleotide polymorphism analyses that can 
pinpoint genetic diversity down to a single-letter difference in a person’s genetic code 
(Genetics Home Reference, 2019). Common DNA variants that are revealed by GWAS 
then become the variants that consumer companies test for when they promise to deliver 
estimates of disease risk to consumers. 
While GWAS and SNP arrays are two of many techniques that have advanced 
human genetics in recent decades, none have left as great a mark on the field as the 
Human Genome Project (HGP), an international, collaborative research endeavor that 
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aimed to sequence the entire genetic code of humanity over the course of a 15-year 
period from 1990–2005. Prior to the HGP, geneticists had a selective understanding of 
the human genome. Some gene families were better understood than others in terms of 
their sequence, function, and location alongside other genes in our chromosomes. But, it 
was not until the HGP that scientists were able to quantify just how many genes humans 
have (20,500) and what the exact sequence, or code, of those genes is (National Human 
Genome Research Institute, 2018). Completed two years ahead of schedule in 2003, the 
HGP resulted in maps of the human genome that provide the instructions as to how 
humans develop, how biological processes unfold, and how disease takes shape. We 
know now that the human genome is comprised of exactly 3.2 billion base pairs of 
adenine, cytosine, thymine, and guanine (ATCG), nucleotides in all of our cells that make 
up DNA (Chial, 2008). When even one of those nucleotides is mutated or missing, the 
code is thrown off, which can result in happy accidents like the ability to taste (and 
enjoy) cilantro but can also cause dangerous diseases if that mutation occurs in a gene 
that is vitally important. Thus, the ability to pinpoint exactly where in the genome 
mutations occur has transformed the possibilities of modern medicine and diagnostics. 
Another key finding of the HGP is that the genetic code of humans is 99.9% identical, 
i.e., my pattern of ATCG is 99.9% the same as any other human (Chial, 2008). The whole 
of human diversity can thus be attributed to a minute fraction of difference between us 
all, and it is that minute fraction that scientists spend most of their time trying to 
understand.  
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Organizers of the HGP had hoped to use the project to begin characterizing the 
function of each and every gene and the molecular mechanisms that contribute to each 
and every disease, but with the technology available at the time, it took 13 years solely to 
capture the sequence and map of the human genome. Much of the data analysis from the 
HGP has occurred in the 17 years since the project was completed as methods and 
diagnostic technologies have developed (National Human Genome Research Institute, 
2018). The advent of these technologies—SNP arrays, GWAS, and other machines and 
protocols—has lowered the cost to conduct genetic analyses and quickened the pace at 
which results are disseminated. In a sense, technological development, information 
sharing, and laboratory analyses all enable each other in a cycle that allows the mass 
exploration of the human genome to occur.  
Taken together, these advancements paved the way for a “second wave” of 
DTCGT that launched in 2007 with genetic testing firms such as 23andMe offering 
health risk testing for a variety of common diseases, such as asthma, diabetes, and stroke 
(Hogarth and Saukko, 2017). A rise in consumer interest in genealogy was burgeoning at 
the same time, and science rose to meet the demand: ancestry genetic testing found its 
own popularity in the 2010s for its ability to pinpoint a person’s geographic and ethnic 
heritage and reveal a percentage breakdown to the age-old question of “What are you?” 
(Bowen and Khoury, 2018). As interest grew, technology advanced, and cost for both 
researchers and consumers fell, DTCGT boomed, and hundreds of firms began to join in 
on the personal genomics market in order to sequence, analyze, and interpret the genomes 
of individuals.  
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More recently, the MIT Technology Review marked 2017 as “the year consumer 
DNA testing blew up” (Regalado, 2018). With the industry reporting a commercial 
market of more than 26 million people, more consumers have purchased DTCGT in the 
past two years than all previous years combined (Regalado, 2019). Leading the personal 
genomics market are testing firms AncestryDNA and 23andMe, which together have 
some of the world’s largest collections of human DNA stored on their databases (Crow, 
2019). Further, researchers estimate that these two private firms are on track to own the 
genetic makeup of more than 100 million people within the next two years (Khan and 
Mittelman, 2018). While 23andMe began as a disease risk testing company and 
AncestryDNA as genetic test for consumer genealogy research, today both firms provide 
both ancestry and disease risk testing as they have risen in the testing market and 
emerged as leading competitors. As such, both firms wield influence over personal 
genomics as their popularity enables them to set precedence for how the market evolves 
and operates.  
My interest in this topic began during my undergraduate education when I was a 
student of genetics. I fell in love with the science of the field, with how predictable our 
cells can be—an almost poetic assembly of genes, proteins, and enzymes that regulate 
our bodies and maintain our existence. One mistake in the replication of a gene can result 
in an onslaught of downstream effects that, with the right research question, can come to 
be treated with a drug or therapeutic gene editing technique in due time. I believe in the 
potential of what genetic research can do for an affected individual; yet, throughout all of 
my studies in genetics, not once did we have a substantial discussion about what it would 
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mean for that affected individual to receive therapeutic genetic treatment. In the context 
of this study, what does it mean to have the ability to unearth a person’s family history or 
risk for disease? What are the individual and societal implications of such a remarkable 
technology? 
I graduated from my genetics education in 2017 during a poignant moment not 
only for the development of consumer DNA testing, but for the advancement of science 
in general. The first half of 2017 saw the inauguration of Donald J. Trump as president of 
the United States, and with his transition into power, a shifting policy agenda that often 
felt as if it was targeting the sciences that I had just spent four years studying intently. For 
example, in week one of the Trump administration, an immigration ban was enacted “to 
protect ‘the United States from foreign nationals entering from countries compromised by 
terrorism’”, which resulted in international students from universities across the country 
being detained at airports or sequestered in their home countries, rather than returning 
from their winter breaks abroad to continue their studies here in the U.S. (Shear, Kulish, 
and Feuer, 2017, para. 33). Much of the scientific research that occurs at the university 
level is conducted by international graduate students who comprise 5.5% of American 
higher education, or more than one million students in 2019 (Institute of International 
Education, 2019). Yet, for a period of 90 days in 2017, their research and studies were 
stagnated and their character questioned in an executive order that burgeoned on 
unconstitutional and, at worse, xenophobic.  
Still, the administration’s policy changes did not stop in week one; they continued 
next by censoring the language used by federal agencies, including barring the words 
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“evidence-based,” “science-based,” “vulnerable,” “entitlement,” “diversity,” 
“transgender,” “fetus,” and “climate change,” in official documents and websites (Belluz 
and Irfan, 2018). Reportedly, the administration also de-staffed the science division of the 
White House Office of Science and Technology Policy, removed scientific advisory 
positions for the Environmental Protection Agency, and slashed research funding for a 
number of federal agencies, including the National Institutes of Health, Department of 
Energy, National Science Foundation, the National Oceanic and Atmospheric 
Administration, Department of Agriculture, and some programs at the National 
Aeronautics and Space Administration (Carter, 2017; Science News Staff, 2017). And, 
against the backdrop of the worst climate crisis society has seen in history, the 
administration withdrew the United States’ from the Paris climate accord in June 2017 
and has since rolled back nearly 100 climate and environmental policies aimed at 
conserving the planet for future generations (Shear, 2017; Popovich, Albeck-Ripka, and 
Pierre-Louis, 2020).  
To be a graduate in 2017 when the headlines funneling from the White House 
appeared to dispute science and scholarly expertise was enough to embolden me to 
become an advocate for science in some way. My personality has always had a social 
justice edge; I have been concerned with society’s unequal distribution of rights and 
privileges from the time I became aware of worldly happenings as a young teenager. In 
the landscape of 2017 American politics, I found a way to marry this edge with the 
sciences that I love—through a study of DNA testing that was exploding in a consumer 
market. In a large sense, I feel accountable for the genetics education I received over 
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those four years. I understand how a saliva sample travels from the home of a genetic 
testing consumer and into a diagnostic lab at one of these gentech firms; how it is mixed 
with chemicals, spun down and resuspended, and stripped of its properties until all that is 
left is human DNA, amplified hundreds of times over and analyzed on microchips, 
turning what was once material into something quantifiable: codified, digitized, and 
readable. I understand it, and so I feel a responsibility to be its gatekeeper. In the health, 
self-tracking landscape of 2020, much of that gatekeeping requires shining a light on the 
ways that a for-profit gentech company can utilize consumers’ personal genetic data, 
especially when little to no governmental oversight is applied to the consumer genetics 
industry, with the hope that illumination will prompt more transparency from gentech 
companies and inspire more scholarly inquiry into this topic that is ever-present and 
continually developing.   
As such, this study seeks to investigate what discourses of DTCGT are 
documented in journalistic reporting and the extent of which news media discourses 
make ethical arguments about DTCGT. I coin this a “socio-ethical discourse analysis” so 
as to keep attention on the ethical, legal, and social implications of DTCGT throughout 
this work. While an assemblage of relationships between government, technology (both 
gentech and biotechnology firms), economic, and political sectors is pronounced in 
DTCGT, my goal is to keep questions of ethics—Should we do this?Is it fair to do 
this?—at the forefront in hopes of prompting further understanding on the issues raised in 
this thesis.  
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Therefore, throughout this work are framings of genetic knowledge that place 
personal genetic data in relief with understandings of digital data as something that is 
both “lively” and commodified, as something to be interpreted within a system of values 
and individual identity. Beginning from Deborah Lupton’s research on the “quantified 
self,” I use the framework of datafication to trace how DTCGT translates the corporeal 
body into a readable format of genetic data visualizations. In doing so, I aim to 
understand how genetic data have manifested as valuable sources for self-knowledge that 
hold the potential to influence humans’ actions. This quest for genetic self-knowledge 
can be viewed through the lens of Michel Foucault’s conception of “technology of the 
self,” positioning DTCGT as a tool that consumers employ to deepen their 
understandings of their own identities and quests for self-improvement. This constant 
mode of health self-management is reaffirmed by Nikolas Rose’s work on biocitizenship 
that prompts consumers to take charge of their own genetic health. Finally, literature on 
uncertainty and risk helps to contextualize the experience of being genetically at-risk for 
a disease revealed by the consumer testing experience. Through these frameworks, I will 
examine the translation of genetic makeup (in the physical) to genetic data (as the 
immaterial) as a concept that forms the basis of a successful business model that gentech 
firms have recognized and profited off of through a socio-ethical  discourse analysis of 
DTCGT in news media discourse.  
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CHAPTER ONE 
 
LITERATURE REVIEW 
 
 
Eugenic beginnings 
While scholars have theorized for decades about what the advent of personal 
genomics could mean for society, in a sense, the popularity of DTCGT took off before its 
ethical consequences could be widely investigated. The presence of consumer genetic 
testing technology now requires that ethical inquiry, especially in light of a history of 
genetic sciences that has almost always been wrapped in controversy. DTCGT does not 
represent the first instance in which the state—governments and private industry—has 
become intertwined in the corporeality of its citizens. The past shares multiple moments 
with the present when the health of a population was determined by the genetic “stock” 
of its people and was moderated by practices that sought to improve the biological quality 
of the population as a whole (Zimmer, 2018a). Coined “eugenics” in 1883 by Sir Francis 
Galton, the movement formed a set of beliefs and practices that encouraged healthy 
people to reproduce so as to maintain a fit, productive human race (Claude Moore Health 
Sciences Library, 2004). Termed “positive eugenics”, the early movement focused on 
encouraging “physically and mentally superior members of the population” to choose 
partners who shared the same qualities as a way of selectively breeding a stronger human 
race (Aubert-Marson, 2009). Later, the writings and research of the “Father of Genetics”, 
Gregor Mendel, paired with Galton’s insights to explain how healthy traits are passed on 
in humans at a time when genetic inheritance was first being characterized and 
understood (Zimmer, 2018a). As the movement continued into the 20th century, its 
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messaging became more ominous through the oppositely termed “negative eugenics” that 
regulated the “weak” out of reproducing (Aubert-Marson, 2009). Government-instated 
policies attempted to eliminate disease, disabilities, and other qualities deemed 
undesirable via practices like the sequestration and sterilization of the mentally ill and 
restrictions on interracial marriage (Norrgard, 2008). The “feeble-minded,” “morons,” 
those who carried a low “intelligence quotient,” or IQ—history painted them as having 
been failed by their heredity because their family’s genes, when swapped together, 
resulted in mental illness and disability (Zimmer, 2018a). Women were blamed for 
having borne mentally ill or racially mixed children, that if only they would “conform to 
the conventions of society,” or keep the company of “intelligent and humane people,” 
their children would not be “degenerates” (Zimmer, 2018a, p. 85).  
Scientific racism was another core tenet of 20th century eugenicists, who argued 
that African Americans carried a propensity for unintelligence and criminality. Crucial to 
the protection of white supremacist systems at the time was the “one-drop rule,” which 
considered those with just one African American ancestor (or “one drop” of black blood) 
as racially black in the eyes of the law, leading to segregation and restrictions on voting 
in some states (Davis, 2001). Though it was not widely acknowledged across the country, 
the one-drop rule was founded on the backdrop of slavery and served as one of many 
cultural definitions of blackness in the U.S. in the early 20th century. Even poverty carried 
a hereditary stigma within the eugenics movement, the argument being that “the destitute 
didn’t have the foresight to save enough money,” and thus passed traits of penury and 
“feeblemindedness” onto their children (Zimmer, 2018a, p. 101).  
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Eugenics and its demoralizing policies began to lose popularity near the end of 
World War II when the liberation of Nazi concentration camps revealed the horrors of 
human experiments to a world formerly unaware that eugenic beliefs were being enacted 
in such ways. However, eugenics’ stain on history lived on as it took decades for forced 
sterilization and discriminatory marriage laws to be repealed in the U.S.—a span of time 
that allowed social concepts of an idealized human race to persist, undoubtedly 
contributing to discriminatory stigmas that exist still today.  
This recognition—that the health of a population can be (and has been) pinpointed 
to a hereditary component—is where this upcoming study finds its significance. 
Eugenics, at its core, was premised upon a desire to improve the human species, to make 
individuals healthier and more intelligent at any cost, and along the way, the movement 
wrapped itself up in dangerous discourses that hurt and demoralized many. While 
personal genomics technology (gentech) companies like 23andMe and AncestryDNA 
base their missions on acquiring genetic self-knowledge or taking a “genetic journey” for 
consumers to better understand themselves and their health, the implications of the 
technology tiptoe a line that could err toward eugenic tendencies if scientists and 
regulators are not careful. A consumer saliva test for health conditions could set 
precedence for a mandated genetic screening that stigmatizes the at-risk from the non-risk 
or reveals the haves from the have-nots if too much state intervention is allowed. The 
results of testing—currently sent to third-party biotechnology (biotech) companies for 
research to help identify genetic causes for traits and disease—could conjure up the 
question of therapy vs. enhancement. That is, at what point is a genetic intervention 
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bringing a patient to a comfortable level of function, as opposed to augmenting the 
human condition with elite capabilities? Critics, like those at the Genetic Literacy Project 
(2013) and geneticist and author Ricki Lewis (2014), would caution that these ethical 
scenarios are radical and that genetic technologies today should not be confused with 
eugenic practices of the 20th century. I propose that consumer genetic testing has invited 
novel inquiry that requires an analysis of its ethical, legal and social implications in order 
to put the best interests of the consumer first and also to establish a pretext for gauging 
how far we as humanity will go in our entanglements with the human genome.  
Today’s ethical, legal, and social implications  
With the growing popularity of DTCGT comes an amplified discussion both in 
scholarship and the public discourse about the ethical, legal, and social implications of 
genetic testing from a number of angles. For example, researchers have raised questions 
about the effectiveness of the terms and conditions agreements or privacy policies that 
precede the purchase of consumer genetic tests in light of studies that show most users do 
not read the fine print of the services they are submitting to (Obar and Oeldorf-Hirsch, 
2016) and that the specific policies distributed by DTCGT companies are often unclear 
and incomplete (Christofides and O’Doherty, 2016; Phillips, 2017). Other scholars have 
questioned the accuracy of genetic testing, given that companies all have their own 
unique algorithms and reference genomes for analyzing an individual’s DNA, resulting in 
different percentage breakdowns depending on how diverse the reference genome is 
(May, 2018; Smart, Bolnick, and Tutton, 2017) and how the algorithm is designed 
(Tandy-Connor et al., 2018). Other authors asks whether it is appropriate to offer genetic 
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testing without supervision from a medical provider (Smart, Bolnick, & Tutton, 2017); 
whether genetic predispositions should be shared with health insurance agencies; and 
whether gentech companies should be allowed to sell consumer genetic data to advance 
research into disease and ancestry (O’Doherty et al., 2016) or share those data with law 
enforcement agencies in order to catch suspected criminals (Rothstein and Talbott, 2006). 
Permeating throughout the ethical discussion is the recognition that consumer-based 
genetic testing is an unregulated industry that is allowed to operate like the “Wild West” 
(May, 2018). As such, perhaps the most necessary lines of inquiry are those that ask how 
governing entities should instate policy to reel in an industry that has otherwise been able 
to evade oversight. 
However, there is an important acknowledgement that needs to be made and 
examined before calls for regulation can be seriously considered, an acknowledgement 
that is often glossed over in the literature on the topic of DTCGT: The very act of spitting 
into a vial and shipping that saliva to a gentech company is political. The information 
contained within our saliva and the impacts that information can have on society may be 
thought of in terms of what Langdon Winner described more than 30 years ago as an 
“inherently political technology.” That is, its application in the realm of DTCGT 
complements the conditions necessary for human associations (1980, p. 123). Humans 
are involved at every step of the testing experience: From the moment a consumer genetic 
test is manufactured, packaged, and shipped to a customer; to the moment a consumer 
collects their saliva and sends it back to the gentech firm; to the preparation of the sample 
and the analyzing of the consumer’s DNA. All of these acts require the work of retail 
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workers, postal workers, consumers, lab technicians, and the web of corporate employees 
and executives who maintain the infrastructure and functioning of a gentech firm. 
Importantly, these human connections also represent the community who has invested 
interest in the culture that genetic testing has created: the family member on Facebook 
who “liked” their niece’s status after she shared her AncestryDNA results, the friend who 
then went and bought his own ancestry test after seeing the same status, the journalists 
who have been documenting this phenomenon, and the government officials who have 
taken notice. DTCGT has created a technological system that maintains a cascade of 
human associations, and it has emerged as yet another outlet for humans to understand 
themselves on a deeper, more personalized level.  
In this work, I align myself with Winner in that I believe it is “the things 
themselves” that can explain this cultural phenomenon (1980, p. 123). Rather than 
reducing the popularity of DTCGT to an assortment of social or technologically 
deterministic forces, I put my focus on genetic data themselves and the meanings and 
characteristics they enact. This focus, coined the theory of technological politics, can 
serve as a complement to other theories of social or technological determinism by taking 
“technical artifacts seriously” (Winner, 1980, p. 123). In doing so, it becomes possible to 
acknowledge the political-economical-technological ensemble of relationships that take 
place in a culture where technology is interwoven. Specifically, I traced DNA and its 
transition from “the carrier of genetic information” to its datafied articulation as a code 
that can predict a person’s health risk or ethnic beginnings. Just as Winner (1980) showed 
for the atomic bomb, cotton-spinning mills, and other artifacts of the 20th century—
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DTCGT exemplifies how “scientific knowledge, technological invention, and corporate 
profit reinforce each other in deeply entrenched patterns that bear the unmistakable stamp 
of political and economic power” (1980, p. 126) and it is the articulation of power that 
necessitates a deeper inquiry into DTCGT.  
Thus far, I have reviewed the genetic sciences’ roots in eugenics, how its 
advancement in the 1990s gave way to consumer genetic testing, and the varying ethical 
questions that arise from DTCGT. I will now turn to the theoretical frameworks that 
precede this study: those of risk and uncertainty, datafication, governmentality, and 
biopolitics.  
Risks and uncertainties about testing 
 As a tool that conveys information to consumers that guides medical decision-
making and develops genetic self-knowledge, DTCGT can yield insight as to how 
consumers receive risk information and manage uncertainty about genetic testing results. 
Uncertainty refers to situations in which the outcomes are unknown or ambiguous, due 
either to a lack of information or the inability to fully understand the information at hand 
(Brashers, 2001; Gesser-Edelsburg & Shir-Raz, 2016). DTCGT delivers predictive 
estimates of a consumer’s disease risk or ethnic background that are based on statistical 
and probabilistic analyses; thus, reducing a genetic outcome to a perceived chance or 
likelihood of happening also confers a level of uncertainty with it. Consumer responses to 
genetic testing are experiential; as Brashers (2001) theorized, uncertainties play out 
amidst a web of multilayered, interconnected, and temporal contexts that make the risks 
conveyed by testing all the more complex to process. Consumers often experience their 
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uncertainty by questioning themselves, their ability to manage their disease risk, the 
effect of that risk on their families and relationships, and the relation of disease risk to 
other social contexts, e.g., “Can I pass this onto my children?” “Will I have to monitor 
this risk for the rest of my life?” “Can I afford the treatment if I get this disease?” “Is 
there even a treatment available for this disease?” Thus, engaging in uncertainty and risk 
management involves cognitive and emotional appraisals as consumers attempt to gauge 
what meaning and relevance the risk has for their lives (Oliveri et al., 2015). Risk 
experienced as a threat or danger to health might confer negative emotions of fear and 
anxiety, whereas mild to moderate risk might yield indifference or even inspire positive 
feelings of hope for a healthier future.  
 Following cognitive and emotional appraisals, consumers’ responses to uncertain 
risks often include information-seeking behaviors that help to negotiate and manage what 
comes next after receiving testing results (Brashers, 2001). For consumers, “information 
gathering serves the purpose of differentiating options, finding options, and creating 
options” as a way to increase knowledge about an outcome and reduce uncertainty 
surrounding it (Langer, 1994, p. 45). As such, consumers may seek varying sources of 
information by consulting with their doctors, researching online, or joining support 
groups in order to interpret their testing results. However, for other consumers, avoiding 
information and maintaining uncertainty might serve as a better coping mechanism if a 
genetic testing result is too overwhelming to handle (Brashers, 2001). Consumers might 
also reappraise their situation and adjust the object of their uncertainty so as to minimize 
its effect moving forward, e.g., consumers at-risk for a disease with no treatment or cure 
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might abandon information-seeking behaviors and pursue other ways of accepting their 
diagnosis (Babrow, Kasch, & Ford, 1998). This process—of identifying an uncertainty, 
appraising it cognitively and emotionally, and then seeking information to negotiate a 
risk—can be affirmed by Affifi and Weiner’s (2004) theory of motivated information 
management (TMIM) that situates uncertainty and information-seeking in three phases of 
evaluation, interpretation, and decision. A key feature of the TMIM is that anxiety is 
viewed a mediator that motivates a person to reduce uncertainty about a risky situation; 
this point differs from other communication theories that purposefully distance “anxiety” 
from “uncertainty” so as not to confuse the two experiences as synonymous (Brashers, 
2001; Oliveri et al., 2015). Further, the TMIM focuses on self-efficacy, or the belief in 
the self to successfully attain an outcome, as an important mediator for decision-making. 
Thus, the TMIM proceeds as 1) identifying the uncertainty and the feeling of anxiety that 
follows, 2) assessing outcomes and negotiating efficacy beliefs, and 3) deciding on a 
strategy to seek information, avoid additional information, or reappraise the situation 
(Affifi and Weiner, 2004).  
 Just as uncertainty is experienced in regard to contextual and temporal qualities, 
Russell and Babrow (2011) contend that risk, too, is a “conceptual and experiential 
phenomenon” (p. 244) that is socially constructed and temporally located. The 
researchers argue that risk is shaped by the narratives that society shares about their 
experiences with risk, and as those stories are shared, the risk at hand is granted more 
agency, meaning, and context for others. This is how individuals develop their own 
“perceived likelihood that a particular event will lead to certain consequences” (Russell 
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& Babrow, 2011, p. 244). People judge for themselves how much weight to ascribe to 
risky events of the past in order to prevent undesirable events of the future. In the case of 
DTCGT, consumers must interrogate their family history of disease is in order to decide 
how meaningful a test for genetic risk might be. These interrogations with risk-making 
burgeon on what Brashers (2001) referenced as the divide between the “chronically ill 
and worried well” (p. 487). The more consumers track their digital and genetic data, the 
more salient “health” becomes on their minds and the more necessary it becomes to attain 
an idealized version of whatever “health” is. But in the quest to deepen genetic 
knowledge and adopt healthier habits comes increased anxiety about disease and illness 
in general, to the extent that society has developed its own a preoccupation with risk. The 
abundance of data technologies for monitoring health only heighten anxiety and 
uncertain, risky behaviors. 
The datafication of genetic makeup 
In 2020, data are seemingly everywhere, permeating throughout our lives in the 
social media we consume, the websites we visit, the apps we use, and beyond. We get in 
our cars and turn on our GPS to get to our destination; we swipe our IDs to access our 
office; we walk to our desk, the hallway illuminated by motion-sensor lights so as to 
conserve energy only when a human is in the room. At each point, data are being 
gathered, locating our driving routes and recording the time we arrive at the office or the 
number of times the lights are activated in a day. Authors have used the conceptual 
wordplay of “everyware” (Greenfield, 2006) and “everywear” (Gilmore, 2015) to 
describe the ubiquity of data-capturing technologies that exist in our spaces on our 
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bodies, respectively. However, the inclination to measure and record our everyday 
experiences is nothing new, as documented by Mayer-Schonberger and Cukier in their 
2013 book, Big Data: A Revolution That Will Transform How We Live, Work and Think. 
While data are seemingly everywhere (everywear, and everyware), the modern “move to 
big data is a continuation of humankind’s ancient quest to measure, record, and analyze 
the world” that is made more salient by the IT revolution and the last 30 years of the 
Internet’s development (Mayer-Schonberger and Cukier, 2013, p. 76). Yet, datafying—
quantifying that which is unreadable—can be traced back to the earliest civilizations 
around 3000 B.C. and the basics of counting and measuring lengths (Mayer-Schonberger 
and Cukier, 2013).  
The shift “from atoms to bits” reflects a tenet of datafication: that at one point in 
the now-present future, most anything that exists physically will have the potential for 
being digitized or datafied (Negroponte, 1995). The human body is no exception. With 
the prevalence of self-tracking health apps that can do everything from counting calories, 
to locating running routes, to measuring sleeping habits, the body is viewed as a source of 
information that people are tasked with interpreting independently. This tracking of 
personal information serves to develop a “quantified self” that helps users optimize their 
lives, their health, and their knowledge of themselves (Lupton, 2016, 2017). Self-tracking 
positions the body as a matter of big data to be read and analyzed, converting the body 
and its corporeal properties into digital texts “of which users are at the same time the 
content and the reader” (Turrini, 2018, p. 6).  
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Likewise, the translation of the body into information is an embodied practice; it 
is the physical manifestation of what was once undetectable grafted onto the human body. 
This liveliness of data is furthered by a community of consumers who have bought into 
(or downloaded into) the self-tracking health market. By sharing results online and 
discussing them with friends and family, digital data take on their own social lives, and 
our corporeal bodies break through into a “network society” where they circulate in their 
datafied form (Castells, 2012). As Levina (2010) writes, the network society is premised 
on the continual reengagement with genetic data in Web 2.0 social networking spaces, 
such as Facebook and Twitter, that emphasize virtual communities, user-generated 
content, and participatory culture with that content. Gentech firms promote this sharing of 
genetic information because sharing is precisely how the network society prospers—it 
“enables a fast and expansive network growth,” by allowing more users to be reached by 
DTCGT, creating the potential for new consumers, (Levina, 2010, p. 2). Users’ actions, 
or shares, gain value as more consumers purchase genetic tests; thus, users are 
participating in a realm of “citizen bioscience,” in which their genetic data become the 
commodity on which the network society functions (Rose, 2007).   
However, the sharing of data online—sometimes taking data tracked by one 
company and sharing it on the platform of another—opens the door to “dataveillance,” in 
which users are constantly monitored on the basis of their online lives and digital data 
(Van Dijck, 2014). Herein lies the issue with datafication of genetic makeup—as found in 
the terms and conditions agreements of nearly any social app or website, once users post 
their data to a social feed, those data essentially become the property of the company and 
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the user loses rights to how their data are handled (Christofides and O’Doherty, 2016). 
Lupton (2017) purposed that users are often left in the dark about this process, unsure of 
how their data are generated, how they are being surveyed by data owners, or how their 
data are used and repurposed by data owners. Many users have reported feeling 
immobilized by data-capturing techniques and their particulars in a progressively tech-
oriented world. The possibilities of what their genetic data can do for disease research or 
pharmaceutical development are enticing for consumers and thus provide incentive for 
purchasing DTCGT. In turn, the process of engaging with data and being surveilled is 
“pleasurable,” as Whitson (2013, p. 164) describes, because the result is an 
entrepreneurial pat on the back for having donated data to a greater cause, all the while 
improving the self.   
While digital and genetic data are themselves immaterial, they are predicated on 
material conditions of the self. Like digital data, genetic data cannot be heard, smelled, or 
felt—but they can be seen through data visualizations, such as graphs, tables, and reports 
that are generated by data owners, like 23andMe or AncestryDNA. Genetic data are 
synonymous with understandings of digital data, in that that the very act of spitting into a 
spittoon is “a culturally relevant instance of converting the body into information” 
(Turrini, 2018, p. 6). Much of the communication and sociological literature on self-
tracking has concentrated on health apps and websites dedicated to movement, exercise, 
and general wellness; however, I am fascinated by the translation of genes contained 
within our physical bodies to traceable “raw” data, a digital sequence of the genetic code 
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that is homed on the Internet’s cloud (Gitelman, 2013). As it relates to this work, the 
datafication of genetic makeup forms the foundation such that DTCGT is able to exist. 
I draw a parallel to Lupton’s literature on the quantified self to identify, indeed, 
that genetic testing consumers have become quantified by their genetic self-knowledge 
and that they have invested trust in what their genetic data mean for them. However, 
Lupton’s quantified self does little to contextualize what is next. What can social science 
scholarship do to complement the quantification of genes? One possibility is Lupton’s 
connection to digital biocapital: the deployment of personal data as a commodity. In 
Lupton’s (2016) estimation, “Biocapital involves the derivation of value from biological 
entities such as human bodies” (p. 117). That is, in the quantification of genetic material, 
the body and genes themselves can be viewed as sources of value because the knowledge 
generated by analyzing them pays kindly for both the consumer and the state. The former 
benefits from a knowledge of self that helps to quell curiosity and uncertainty about 
family heritage or health predispositions, and the latter benefits from the purchase of 
goods (e.g., supplements, gym memberships, further diagnostic care) by the consumer to 
extend interactions with data. Both are positioned within a system of knowledge and 
power, which as Michel Foucault explains, reinforce each other. Knowledge is 
information gained through institutions, be it from books, school, or in this case, 
DTCGT; power is allowed to exist because of this knowledge, and it exploits knowledge 
in order to reimagine what knowledge can be (Foucault, 1977; Foucault, 1980). Thus, the 
power/knowledge couplet within DTCGT is premised upon a consumer who is 
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encouraged to engage with their data and a private gentech company that continually 
creates new opportunities for data engagement.  
Before the datafication of genetic makeup, the sort of self-knowledge granted by 
DTCGT was not readily available to consumers without hundreds of dollars or the 
direction of a medical provider. For most, they could not fathom that within a few years, 
and for the discounted price of $49, they could receive their genetic profile as a 
Christmas gift. Consumers’ progressively growing interest in DTCGT has placed a 
critical focus on the companies that store their data and just what, exactly, those 
companies intend to do with them. Just as health data are susceptible to dataveillance, so 
are genetic data; thus, I aim to draw a parallel between datafication research and the 
genetic testing experience to uncover what value DTCGT companies find in their users’ 
genetic data and how that value translates into genetic data being commodified. The 
construct of the consumer, gentech companies, and the regulating bodies that oversee the 
testing experience forms a hierarchical system of relationships—micro, meso, and macro 
respectively—where data are valued and power is expressed from the top, down. The 
understandings mentioned here of biocapital, power/knowledge, and commodity are 
further explicated by Foucault’s ideas of governmentality.  
Genetic data as a form of governmentality 
A cornerstone of Michel Foucault’s concepts of governmentality and biopolitics is 
the premise that before individuals can be controlled or managed by a system of power, 
they must first know themselves in order to define their own identity (Foucault, 1988). 
Through the acquisition of self-knowledge, humans gain an ethical understanding of who 
 24 
they are and what their standards are, and only once this self-knowledge has been 
obtained can the process for self-care begin. Upon the recognition of self, processes of 
human life become susceptible to management by a regime of authority, one that has 
control over knowledge and power—even going so far as turning citizens of the state into 
puppets of the state. Biopower, to Foucault, serves as a technology to manage large 
groups of people, allowing for the eventual control of an entire population. Managing 
biological lives and sorting people into categories stand as both economic and political 
strategies to ensure the welfare of the state, because if you can manage a human, you can 
make him/her/they a productive member of society (Foucault, 2010). Importantly, the 
meaning of “productivity” in Foucault’s framework references the ability of a citizen to 
contribute to the economic well-being of the state. To foster that productivity, Foucault 
describes a collision of technologies of the market and technologies of the self—the first 
describing the things that we buy and sell to benefit our economy, and the second 
describing the things or practices that we individually adopt to better our quality of life 
and deepen our self-understanding (Foucault, 2010). These two technologies couple to 
produce a “technology of power” that serves as the basis for governmentality, in that, 
when individuals contribute to the economy and when they invest in the growth of 
themselves, they can be the most productive members of society, and thus those best 
suited for furthering the government’s success.  
Neoliberalism—a political/economic theory characterized by principles of 
privatization, individual autonomy, unencumbered markets, and free trade—has 
developed Foucault’s technologies of power, market, and of the self by furthering the 
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concept of the individually responsible, self-managed consumer (Harvey, 2007). 
Neoliberalism gained popularity in the mid-20th century as a shift in economic ideology 
from classical liberalism, which many blame for the economic misfortune of the Great 
Depression in the 1930s (Dagger & Girvetz, 2020). As Foucault outlines, neoliberalism 
differs from classical liberalism in a few ways: 1) it dissociates “the market economy 
from the political principle of laissez-faire,” emphasizing instead the constant 
intervention of the government in the construction of the market, 2) it moves from a 
“homo œconomicus,” as a person of exchange to one who is a person of enterprise, 
investing in themselves and striving for self-definition, and 3) it denotes power as exerted 
upon an entire population, rather than the normalization of the individual, i.e., biopolitics 
(Foucault, 2010, p. 147; Foucault, 1978; May, 2012). Neoliberal extensions of 
governmentality emphasize concepts of autonomy and subjectification to negotiate the 
ways in which individuals choose to regulate their health and well-being in response to 
efforts by the state to place responsibility on the individual, rather than society as a 
collective. Power, as applied to the population, asks the individual homo œconomicus to 
develop an entrepreneurial mindset and care for themselves, as care for the self directly 
benefits the population as a whole. Those who fail in their individualized endeavors 
toward optimization bear a responsibility for withholding society.  
Biopolitical examinations into DTCGT emphasize neoliberal governmentality, 
with many beginning their discussions from Abby Lippman’s 1992 “geneticization” 
thesis. This concept, devised by Lippman in anticipation of the rise of genetics as a field, 
refers to the ways that social and health-related activities would come to be defined by 
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genetic terms as genetic research progressed. Lippman predicted a tendency for human 
diseases, behaviors, and even differences between humans to be attributed solely to 
genetics at the expense of the role of environment in a person’s development. While little 
of the geneticization thesis has been realized in the nearly 30 years since it was 
conceptualized (Weiner et al., 2017), sociological scholars point to DTCGT as a “vector 
of geneticization” that places a deterministic emphasis on a person’s genetic identity 
(Hoover and Emerich, 2012, p. 32; Nelson, 2008).  
Here enters the neoliberal term of “individual self-determination,” in that, because 
DTCGT lacks medical supervision, consumers are charged with interpreting their own 
DNA test results and are thus responsible for developing their own genetic self-
knowledge and identity. Users seek out DTCGT in order to optimize their health or 
deepen their understanding of their ethnic breakdown; therefore, DTCGT can be viewed 
as a “technology of the self” that presents a way for users to govern themselves and 
manage their own genes. The results of a genetic test serve as yet another tool for 
consumers to moderate their health behaviors or alter their identities, lending toward the 
creation of a more actualized self.  
The landscape in which users can attain a personalized snapshot of their health is 
what Rose (2008) calls molecular biopolitics, the combination of the “molecular” features 
of humans and the “molar” questions of how to govern others and ourselves. Analogous 
to Foucault’s technologies of power, Rose highlights the concepts of autonomy, control, 
responsibility, and prudence in describing the rise of personalized medicine that created 
DTCGT: “No more ‘one size fits all’, health is a personal matter—indeed a consumption 
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good,” says Rose (2008, p. 437). His work denotes a shift from citizens as patients to 
citizens as consumers who actively choose medicine and treatments to enhance their own 
vitality and self-manage their health, denoting the creation of the biological citizen.  
This biological citizen emerges from a long history of citizenship projects that 
sought to emphasize the ways that authorities envision potential citizens and the ways 
they tried to enact them, e.g., through biological terms of race, blood lines, and 
intelligence. The modern biological citizen diverges from racialized and nationalized 
citizenship projects to underline different ideas about the role of biology in creating a 
human’s worth and different ideas of biological responsibility (Rose, 2007). Today’s 
biological citizen is one who understands themselves at a genetic, molecular level and 
uses that understanding in a collectivized fashion to form biosocial groups around shared 
genetic identity. They are the parents in a Facebook group who support each other 
through the journey of a rare, genetic disorder; they are the activist patients who 
campaign for better access to health insurance or research into an under-funded 
condition. Each instance represents a citizen who has taken the search for scientific 
knowledge into their own hands amidst a bioeconomy that profits off of the generation of 
scientific knowledge. Importantly, “biological citizenship requires those with investments 
in their biology to become political,” in ways that reinforce the market economy of health 
(Rose, 2007, p. 149). By linking to datafication of the body, Rose (2007) explains the 
rendering of bodily processes into economic value: genetic disease is viewed as a 
potential resource of economic opportunity for biotechnology companies through 
privatized funding for research practices and the patenting of inventions like diagnostic 
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testing methods and sequencing machines. These outlets present new possibilities for the 
generation of wealth premised on the body, and as Rose argues, even call into question 
the marketability of ethics that have emerged alongside genetic responsibility.  
Delving further into a Foucauldian analysis of DTCGT, scholars usually take one 
of two directions, highlighting either the emancipatory effects of DTCGT or the 
disciplinary ones (Turrini, 2018). Emancipatory perspectives posit genetic testing 
consumers as “moral pioneers” who mobilize individually and collectively to learn more 
about their genetic health or ancestry without being prompted by a medical provider 
(Turrini, 2018; Rapp, 1988).  Exemplified by Facebook groups and Reddit threads where 
users create community around their genetic testing results, this perspective touts 
“biological citizenship” (Novas and Rose, 2005) in which consumers take responsibility 
for their own self-discovery into their genetic makeup. The consequence of this 
perspective, Rose (2007) describes, is the classification of people into “families, lineages, 
communities, population, and races” that become susceptible to appropriation by 
“interested parties” (Turrini, 2018).  
Alternatively, disciplinary perspectives refer to genetic testing consumers as 
“genetic entrepreneurs” that blend self-discovery with market capital. From this angle, 
empowerment is not the goal and genetic susceptibility is not a cause for alarm; rather, 
genetic testing results are viewed as information that consumers can use to maximize 
their well-being through “hard work as ‘enterprising, self-actualizing, responsible’ 
persons” (Novas and Rose, 2000). Disciplinary perspectives are rooted in market terms 
that view DTC genetic tests as transactional: the genetic entrepreneur purchases a good 
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that benefits the organization of the healthcare market. In this right, users buy into 
DTCGT in part to donate their DNA to advance research into disease, stating that the 
benefit to the “greater good” outweighs the potential costs of their data being sold to 
third-party entities (Halusker, 2019). Through this perspective, consumers are embodying 
the sacrifice of self for the progress of society at large, which is at its core a technology 
of power that assists the goal of governmentality.   
My argument in reviewing this literature is that biopolitical analyses of DTCGT 
do not have an “either/or” outcome. Emancipatory and disciplinary understandings of 
personhood and subjectivity coexist in consumers’ interpretations of their testing results, 
and both understandings should be considered alongside one another when putting a 
critical eye on the consumer genomics industry. Due to threats of commercial misuse, the 
emancipatory calls for appropriation of genetic knowledge must be heeded. With a 
technology that is based upon classifying oneself as “carrier” or “non-carrier,” 
“European” or “African,” the potential for reshaping identities in response to genetic test 
results is possible. The genetic options theory (Roth and Ivemark, 2018) explains just 
how this sort of genetic classification can transform social identity, causing individuals to 
selectively choose which part of their ancestral makeup they recognize. When considered 
in cohort with Foucault’s ideas of governmentality, it becomes probable to envision a 
landscape in which a system of power—or a gentech company—can exploit racial 
divisions to politicize its people, rooting them deeper in their differences rather than 
uniting them in their similarities.  
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However, the disciplinary effects of DTCGT also hold merit. When an individual 
purchases a health genetic test, they do so under the notion that they will receive a result 
that can inform their future health regimen—that is, the knowledge of whether or not they 
are predisposed to a disease based on their genetic makeup will help them to decide how 
they should adjust their diet and/or lifestyle to remain as healthy as possible for as long as 
possible. Harvey refers to this quest for longevity as “enhancing one’s vital capital,” or 
working to ensure “the capacity of humans as living beings” (2009, p. 369). This 
sustained capacity is necessary for members of a society with capitalism as its economic 
system. The longer a human lives, the more opportunities he/she/they have to add to 
society’s economic value. The very act of purchasing a genetic test to attain vital capital 
helps to benefit the economy, as do the subsequent actions taken to achieve a healthy 
outcome, e.g., purchasing healthier foods, dietary supplements, or a gym membership. 
Each choice made in response to a DTC genetic test represents a technology of the self 
and/or market that functions to insert able, productive bodies into the modern capitalistic 
system. However, “moral pioneers” of the emancipatory perspective are not excluded 
from the economic underpinnings of the tests they submit to, just as “genetic 
entrepreneurs” are no less biological citizens.  
These emancipatory and disciplinary distinctions between Foucauldian 
perspectives of DTCGT are thin at best, and it is my intent to examine their blurred lines 
to unite these bodies of literature. Paired with datafication, I am interested in drawing a 
parallel between the collection of genetic data and the capability of those data to be 
manipulated by the “state”—a gentech firm, a health insurance company, or one of the 
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many other biotech companies who come to acquire genetic data through the sale of 
them. Using Foucault’s ideas on biopower, I can trace the subjection that DTCGT 
consumers experience, consciously or not, when they lose ownership of their data by 
signing the dotted line of a terms and conditions agreement. Through this line of inquiry, 
I will attempt to answer the following: 
RQ1: What discourses of DTCGT are documented in journalistic reporting? 
RQ2: To what extent do these articles engage with issues of ethics, if at all? 
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CHAPTER TWO 
RESEARCH METHOD AND DESIGN 
 
Foundations and Approach 
 This study stems from a research question I had when I started graduate school in 
2018: what motivates consumers to purchase genetic testing? When seeking graduate 
programs, I was eager for a social science that could equip me with the tools to answer 
this question, one that could serve to describe the phenomenon of DTCGT in popular 
culture. After all, the social sciences study people, and communication—the field where I 
landed—studies how people talk to each other and how artifacts convey a symbolic 
meaning that frame their conversations (Lindlof and Taylor, 2002).  
 Situated within the study of communication, this research utilizes a qualitative 
approach to elucidate the individual, organizational, and societal implications of DTCGT 
as reported by news media. A qualitative approach was chosen intentionally to answer the 
questions of this study, as I am not looking to impose theory upon the data; rather, I want 
the data to speak for themselves and for concepts to emerge organically. Issues of ethics 
are rich in contextual details; they are not simply black or white, cause and effect. “A 
circled number on a questionnaire is but the tip of the iceberg,” as described by Baxter 
and Babbie (2003, p. 62). Thus, if I am interested in understanding the discourse 
clustering around DTCGT, I must honor the contextual details by using a method that 
helps to construct a qualitative social reality.  
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 This research marks my second line of inquiry into the topic of DTCGT. The first 
occurred in Spring 2019 when I conducted a pilot study using the qualitative interview to 
directly ask consumers of DTCGT how they made meaning of their test results. I asked 
questions in order to capture what motivates individuals to know themselves at the 
molecular level, and I created scenario-based questions that tested consumer knowledge 
of real-world examples of ethically concerning misuses (or potential misuses) of genetic 
data. The results of this pilot study highlighted three leading motivations for participants 
who sought DTCGT: 1) curiosity, or the desire to take part in a newly available, state-of-
the-art technology; 2) family, both using DTCGT to confirm familial relationships and to 
bond with family members over test results; and 3) an indifference to ethics, in that 
participants agreed that the benefits outweigh the risks when sharing their genetic data 
with a biotech company.  
As the researcher, I was rather unsurprised by the results gathered. In approaching 
my pilot study, I suspected that testing consumers likely had not put much thought into 
the ramifications of a DTC genetic test, given previously referenced literature that most 
consumers do not read terms and conditions agreements before submitting their data 
(Obar and Oeldorf-Hirsch, 2016). I anticipated that, “It’s just cool,” would be the answer 
to the question of motivation, because, well, DTC genetic tests are cool. They utilize 
cutting-edge technology that was formerly inaccessible to the public, and they provide 
personalized analyses to an audience of consumers who are inherently self-curious. And, 
to the theme of “family,” I could speak firsthand to the draw of learning about your 
ancestral history after having witnessed my dad’s quest to track his own genealogy for 
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the better part of my life. So, I was not surprised by the themes that emerged from the 
data, but I was left wanting more.  
Enter: this study, my second line of inquiry into this topic. This work utilized a 
different method—discourse analysis—to gain a more holistic understanding of the 
conversations and messages surrounding DTCGT beyond the scope of a small sample of 
participant interviews. In using a second method to expand on my Spring 2019 pilot 
study, I am attempting to triangulate and crystallize the data, two concepts described by 
Tracy (2010). The former represents when “two or more sources of data, theoretical 
frameworks, types of data collected, or researchers converge on the same conclusion” in 
order to generate a more valid study (Tracy, 2010). The latter encourages researchers to 
use multiple methods and sources of data, though not for the purpose of aiding validity; 
rather, the intent of crystallization is “to open up a more complex, in-depth, but still 
thoroughly partial, understanding of the issue” (Ellingson, 2008; Tracy, 2010, p. 844). 
Thus, by taking a multi-method approach through an interview study and now a discourse 
analysis, I am aiming to make my research more comprehensive while also deepening my 
understanding of the topic at hand and allowing for reinterpretation later on. 
Discourse Analysis 
 As described earlier, users of health apps and software are often unsure of how 
their data are used and repurposed by data owners (Lupton, 2017), even though gentech 
companies outline the data’s potential uses in their privacy policies. However, those 
policies are often jargon-filled and glossed over by consumers, which calls into question 
just how informed consumers are about the handling of their data (Obar and Oeldorf-
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Hirsch, 2016; Christofides and O’Doherty, 2016; Phillips, 2017). Journalistic reporting 
serves as one way to elucidate the fine print of such privacy policies and other issues that 
stem from DTCGT. Investigative journalism and news media reporting are regarded for 
their emphasis on facts, truth, and reality, what Zelizer (2004) calls the “god terms” of the 
profession. A core principle of journalism relies on presenting an argument or issue from 
multiple vantage points with factual, informed evidence so as to give the reader a reliable 
account of the issue. The profession is also denoted by being “an independent monitor of 
power” to describe how power is executed in a society and what the effects of powerful 
entities might be for the public (Kovach & Rosenstiel, n.d.). It is these tenets that draw 
readers to news media as they search for an accurate and credible account of current 
happenings in the world, an account that is broken down and summarized for easy 
reading.  
In this study, I looked toward journalism’s capacity to provide information that is 
comprehensive, truthful, researched, and representative of varying perspectives in order 
to carry out a discourse analysis of news articles describing the advent of private firms 
23andMe and AncestryDNA. As defined by Baxter and Babbie (2003), discourse analysis 
“is the qualitative study of constituent units of discourse and how they are arranged in a 
system, structure, or grammar,” where “discourse” refers to language in context (p. 355). 
Rather than examining particular words or phrases in spoken language or written text, a 
discourse analysis considers the social and cultural frameworks in which language is 
enacted. It recognizes that trends in popular culture, such as the popularity of DTCGT, do 
not exist in a vacuum; thus, the conversations around a subject take place among 
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systemic and institutional practices that invoke meaning into dialogue. Just as this study 
attempts to place genetic data within a multiplicity of political-economical-technological 
relationships, the method of discourse analysis places language in context of a subject’s 
history and the societal structures that contribute to it.  
A Foucauldian approach to discourse analysis is amenable to this study of 
DTCGT because it contextualizes language through historical and cultural foundations. 
Importantly, Foucault’s definition of “discourse” focuses on the rules, divisions, and 
systems that define how a particular topic is discussed; these rules and systems are the 
contextual component of language referenced by Baxter and Babbie (2003). Arribas-
Ayllon and Walkerdine (2011) describe three broad qualities that further define a 
Foucauldian discourse analysis:  
1) The analysis involves a genealogical inquiry into the subject of discursive 
practices, such that the subject can be understood in terms of its historical construction. 
When we describe how present discourses are shaped by poignant moments in history, 
we demonstrate that there are prior practices and relationships that serve as pre-
conditions for how we understand discourse today and often, those pre-conditions are 
moral, political, economic, and technical events of the past.  
2) The analysis stresses power relationships that are revealed through language 
and practices. Subjects are contextualized by the intervention of powerful entities, e.g., 
government, technological, or corporate entities that guide how discourse governs the self 
and others. 
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3) The analysis makes reference to subjectification by highlighting techniques for 
self-management and behavior modification. This point asks how an individual tends to 
the relationships and constructs surrounding them to develop their own attitudes and 
morals toward an object. 
Choosing a Foucauldian approach represents an intentional practice of aligning 
this research with the theoretical frameworks of biopolitics and governmentality and the 
history of genetic sciences previously described here. 
Data Collection 
This analysis included articles from U.S. newspapers from 2017 through January 
2020, corresponding with “the year consumer DNA testing blew up” (Regalado, 2018) 
and into the present, in order to document the current phenomenon of DTCGT. Articles 
were pulled from newspapers with the widest circulations—The New York Times, The 
Wall Street Journal, and USA Today—to gather an illustrative corpus of statements 
(Miaschi, 2017; Muck Rack, 2018; Pew Research Center, 2019).  
Initially, I attempted to use NexisUni and Google News to collect the articles for 
analysis. NexisUni allowed for an advanced search option that limited the results to a 
date range, from selected sources, using a specific search term. However, the keywords 
“consumer genetic testing,” only generated 12 results, all of which were from The New 
York Times despite a query from all three sources in this study. Only three of 12 results 
were news articles, while the rest were letters to the editor or articles covering unrelated 
topics. Querying with more specific keywords, such as “Ancestry.com” or “23andMe” 
rendered just as few results. It became clear then that NexisUni was not an appropriate 
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search engine to gather articles for this study. Google News was also limited, as the only 
way to search for articles by source is to use the source as a keyword, e.g., “consumer 
genetic testing” AND “NY Times,” which allowed other sources to populate the results. 
Google News is also unable to customize searches by a specific date range; the most 
exact query I could run resulted in news articles published within the “past year” or 
“anytime,” which made it tedious to search for articles published prior to 2019. I then 
decided to go to each news source’s website to directly search their archives and gather 
articles for the initial sampling, having purchased subscriptions to The New York Times 
and The Wall Street Journal in order to conduct this study. (USA Today is freely 
accessible.)  
Articles were then selected and organized based on the following criteria: 
1. Only articles published between January 1, 2017 and January 4, 2020 were 
included in the initial sampling. 
2. Articles were gathered using the keywords “consumer genetic testing,” 
“Ancestry.com,” and “23andMe.”  
3. Articles not specifically discussing DTCGT, Ancestry.com, or 23andMe were 
removed. Relevance was gauged by the article title, headline, and the first 
paragraph or so of copy that was visible without a publisher subscription.  
4. Selected articles were numbered in an Excel spreadsheet and organized by 
article title, publisher, date published, and keyword.  
5. Any articles that appeared in duplicate were removed. 
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84 articles resulted in this initial sampling: 38 from The New York Times, 30 from 
The Wall Street Journal, and 16 from USA Today. After paying for publisher 
subscriptions and getting past paywalls, I discovered that some articles in full were not 
relevant to the topic at hand and that some Wall Street Journal articles are still 
inaccessible, even with a basic subscription. This significantly impacted the number of 
articles from The Wall Street Journal that I was able to analyze in this study. To further 
narrow the articles for analysis, I used a random number generator to construct a final 
pool of 50 articles: 25 from The New York Times, 15 from The Wall Street Journal, and 
10 from USA Today.  
Data Analysis 
I printed all articles and, for my initial round of coding, used hand-coding 
techniques and an arsenal of highlighters to begin analyzing the data. I employed the 
constant comparative analysis method (Glaser & Strauss, 1967; Charmaz, 2006) to 
identify common themes revealed in reporting about the personal genomics industry. 
Made known by Glaser and Strauss’ grounded theory approach, the constant comparative 
method requires “an ongoing process of comparing units of data with each other,” 
through the development of codes and categories, (Lindlof and Taylor, 2002, p. 250). I 
utilized open coding at the onset of my data analysis to interpret the articles I choose, 
reading them line by line and assigning categories to the data based on my initial 
thoughts and the coherent meanings that are conveyed at the surface-level of the data 
(Strauss, 1987).  
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After open coding, I took three weeks of time away from the articles before 
returning for a second round of coding, calling in the “constant comparative” aspect of 
this method. Walking away from the data, for any period of time, was a way of 
approaching this study with a fresh perspective so as to avoid becoming mired in the data. 
In the second round of coding, I grouped codes under a more generalized umbrella of 
topics, looking specifically for themes regarding neoliberal + governmental + 
bioeconomical understandings of the journalistic discourse on DTCGT (see Table 1.) 
Grouping the original codes in this manner calls in the Foucauldian approach of this 
study by specifically looking for power relationships within the discourse.  
To assist in clarifying what those relationships might be, I employed LeGreco and 
Tracy’s method of discourse tracing to more easily highlight the macro, meso, and micro 
levels of discourse that occur within the topic of DTCGT. Discourse tracing caters to 
critical-interpretative analyses of language, power, and context and seeks to make sense 
of the data gathered by clearly delineating the subjects who wield power within the 
discourse (LeGreco & Tracy, 2009). Micro-level discourse looks at how language is 
produced locally; meso-level discourse is broader, examining the entities and texts that 
organize local examples; and macro-level discourse encompasses even “broader social 
narratives and systems of enduring thought that shape and are shaped by micro and meso 
discourses” (LeGreco & Tracy, 2009). Thus, to elucidate how power is operationalized 
within DTCGT, I examined discourse through the interplay of government (macro), 
gentech company (meso), and consumer forces (micro). In the articles I studied, any 
mention of a government entity, e.g. the FDA, CDC, FCC, or law enforcement, 
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represented a macro-level attempt to regulate 23andMe or Ancestry. These gentech 
companies served as mediators between government and the DTCGT consumer. Through 
this lens, I was able to probe the dataset for power relationships, again, using the 
following research questions: 
RQ1: What discourses of DTCGT are documented in journalistic reporting? 
RQ2: To what degree do these articles engage with issues of ethics, if at all? 
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CHAPTER THREE 
RESULTS AND ANALYSIS 
  
Across the articles I examined for this project, I found that DTCGT was presented 
in terms of its accompanying ethical issues, as if the technology itself cannot be separated 
from the ethical questions that it raises. Not a single article in the dataset was able to 
present DTCGT without discussing at least one of the many problems posed by consumer 
genetic testing. RQ2 asks, “To what degree do these articles engage with issues of 
ethics?” and the answer is simply put: entirely or completely.    
The articles chronicled the breaking news headlines of DTCGT over the past two 
years, from when the FDA first began to allow 23andMe to sell genetic tests for disease 
risk, to the tracking of the Golden State Killer using a consumer DNA database, to 
Elizabeth Warren’s claim of her own Native American ancestry using genetic tests, and 
into more recent headlines, like AncestryDNA breaking into the health testing market and 
genetic testing’s entanglements with child privacy laws. Below are the most salient 
themes found in the dataset, including the issues of ethics that marked each theme.  
Biocitizenship: The self-managed consumer 
Together, these tools [whole-genome scans, artificial intelligence, and targeted 
drug and gene therapies] can empower patients to become co-directors of their 
own medical destinies. In fact, the right to know the risks contained in your 
genetic code will likely become the most fundamental medical right of the 21st 
century.  
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—Huber and Howard, Wall Street Journal 
 The framing of the genetic testing consumer as an enterprising biological citizen 
reverberated throughout the dataset. This theme was characterized by language that 
posited consumers as those who often seek testing without consulting with a doctor or 
genetic counselor because “…people do not always need the intervention of medical 
professionals and genetic counselors to learn their risk for certain diseases” (Kolata, 
2017a, para. 8). For example, in 2017 when articles first began to document the advent 
DTCGT for disease risk, Kolata (2017a) presented the technology as an alternative to the 
clinical genetic test, stating, “until now, the only way for people to get such genetic tests 
was to see a medical professional” (para. 5) but the advent of a consumer option made the 
process all the more “simple” (para. 6). This claim by Kolata highlights the autonomy 
granted to consumers in figuring out their own disease risk or ancestral background by 
using privatized tests rather than clinical ones, an act that embodies neoliberal values of 
caring for the self and investing in one’s own health. Self-investment strengthens the 
subject of the self-managed consumer, who is characterized in the discourse as one who 
seeks “control over their own health information” and uses DTCGT as a tool to “manage 
and monitor their health” (Huber & Howard, 2017, para. 4). As a result of learning their 
disease risks, some consumers manage their health outcomes by adjusting their lifestyles. 
One story from The New York Times spoke of 32-year-old Matt Fender who, upon 
learning from a 23andMe test that he had a genetic variant for early-onset Alzheimer’s, 
sought “to improve his health through diet, exercise and supplements” (Hercher, 2018, 
para. 11). The process, of individually seeking a genetic test and then altering health 
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behaviors in response, demonstrates DTCGT as a technology of the self that consumers 
utilize to maximize their “vital capital” (Harvey, 2009). Micro-level discourses focus on 
the consumer who seeks healthier habits so as to stave off the likelihood that their 
increased genetic risks will be realized—but doing so implicitly reinforces the idea that 
“health” is the optimal state for which all citizens should strive. The healthy body is the 
morally acceptable body, and neoliberal principles encourage that the individual is 
responsible for attaining a state of health that ensures their ability to contribute to society. 
In responding to his genetic test with healthy behavior modifications, Fender exemplifies 
his own capacity for self-governance that in turn grants him more opportunity to be 
accepted and to participate our capitalistic system.    
 However, the story of Matt Fender also represents the opposing frame of the self-
managed consumer that was presented in the discourse. While 23andMe told Fender that 
he was certain to develop Alzheimer’s in his lifetime, AncestryDNA found no genetic 
marker indicating this outcome, leaving Fender “to grapple with the discordant results on 
his own. He felt more than ever in need of a doctor’s advice” (Hercher, 2018, para. 23). 
Indeed, there were many more articles in the dataset that problematized the absence of 
medical supervision in DTCGT. For example, this frame “warns that some consumers 
may be led astray by genetic findings that are overblown or irrelevant” (O’Connor, 2017, 
para. 5) because “in a perfect world, a discussion with a medical provider would still 
happen first, before someone decides whether to get tested and what tests to take” 
(Painter, 2018, para. 11). Taken together, I argue that these articles present a consumer 
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who might misunderstand just how genetic tests achieve their accuracy and convey risks 
about disease.  
Much of this frame implied that when medical professionals are left out of the 
testing conversation, consumers are granted total self-management of their genetic 
outcomes, because few consumers will cross-check their results with clinically proven 
genetic tests unless they receive a result that predicts an increased or almost-certain risk 
of acquiring disease later in life. Even still, several articles encouraged following up with 
a genetic counselor “before taking any action based on test results,” so as to ensure that 
consumers can make fully informed decisions about their health outcomes (Marcus, 
2018b, para. 12). I argue that this frame works to infantilize consumers by suggesting that 
they are not knowledgeable enough, nor do they have the agency, to make informed 
health decisions. Yet, the decision to include or exclude a genetic counselor in the testing 
conversation is still a choice made by the consumer; medical professionals serve as 
another source of information that the consumer can choose to include or exclude in order 
to better understand their genetic risks. If the self-managed consumer is defined by 
qualities of autonomy, self-determination, control, and responsibility over health 
outcomes, then the decision to seek medical advice—or even the decision to take test 
results at face value—are valid responses to DTCGT that do not diminish the agency of 
the consumer.   
 But, the accuracy of consumer tests is inherent to the genetic testing experience, 
and thus represents an important feature of genetic testing that the self-managed 
consumer must take into account. Accuracy of tests was a code that appeared repeatedly 
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across the dataset and was defined by its deep dive into the science of health and ancestry 
genetic testing. From the health perspective, clinical genetic tests are designed to be 
much more comprehensive in testing the genome than consumer tests are. For example, 
The Editorial Board of The New York Times contends that 23andMe “relies on much 
simpler technology than tests that you’d get at your doctor’s office” (para. 2). 
Importantly, consumer tests from 23andMe and Ancestry only take into account “just a 
handful of places in the gene where mutations are known to appear” (The Editorial 
Board, 2019, para. 10). However, most diseases are complex and result from an interplay 
of multiple genetic mutations or even just one mutation in a gene that is not included in a 
consumer test. As Roni Caryn Rabin’s New York Times article put it in the example of 
breast or ovarian cancer screening, “testing negative for the three [pathogenic] mutations 
does not mean someone is in the clear, as there are over a thousand BRCA mutations 
associated with increased cancer risk,” and those thousand mutations are not presently 
included on the panel tested at 23andMe or Ancestry (Rabin, 2018, para. 5). Testing 
accuracy also takes into account the differences in algorithms and reference panels that 
each gentech company has to work off of. Marcus (2018b, para. 14) writes: “Companies 
rely on proprietary databases and algorithms to make their assessments. Results may vary 
depending on how many people a company has in its database, as well as how diverse 
their backgrounds are.” For the ancestry testing consumer, one USA Today article posited 
that “ancestry testing is no exact science…data about your heritage are determined by 
comparing users to a reference database of other users. And each company has its own 
proprietary algorithm and dataset” (Farr, 2018, para. 10–12). 
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Accuracy of genetic testing and the potential for inaccurate test results is thus 
presented in the discourse as a risk that consumers need to be mindful of. For the self-
managed consumer on a quest to deepen their genetic self-knowledge, accuracy is one of 
the more paramount risks to be concerned with. Being led astray by the tool you choose 
to use in monitoring your health or expanding your family tree could result in off-base 
health responses and unconfirmed familial relationships that invalidate the purpose of 
testing in the first place. Yet, accuracy is but one of many risks and uncertainties about 
the genetic testing experience that were documented in the dataset; phrases denoting risks 
and uncertainties about testing came up 20 times across the articles studied (see Table 1). 
“Risks” presented in the articles were twofold: first, there is the inability of 
genetic tests “to describe a person’s overall risk of developing the disease in question” 
(Burton, 2017, para. 4), as “diet, environment, lifestyle, family history and other factors 
play a role,” too (Marcus, 2018b, para. 12); and second, the chance that tests might 
convey a false or inaccurate picture of disease or ancestry is a risk unto itself (Kolata, 
2018). When consumer gentech companies “look for changes in tiny segments of genes, 
rather than examining the entire gene and looking for alterations,” (para. 19) false-
positive and false-negative results can occur, but unlike their clinical laboratory 
counterparts that are subject to regulations and quality controls to ensure error-free 
results, gentech companies absolve themselves of fault “because they make it clear that 
their data are not meant to be used for medical diagnoses” (Kolata, 2018, para. 29). Thus, 
the results received from 23andMe or Ancestry cannot “tell you much about your risk of 
developing the diseases in question” (The Editorial Board, 2019, para. 2). Clearly, the 
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results are an estimate, and proceeding with DTCGT carries with it its own risks and 
uncertainties about the results at hand. To the extent that discourses in these articles 
engage with scholarly understandings of risk and uncertainty, DTCGT serves as a 
testimony that the value of “risks” are to be determined personally, based on the lived 
experiences of the consumer. Participating in daily life where health is an ever-present 
goal means also participating in the constant construction and evaluation of genetic 
risk—taking a genetic test elicits information about risk, which produce actions that carry 
with them their own risks in a cycle that is ongoing.  
For the self-managed consumer, the risk that results might not be as accurate or 
comprehensive as hoped for can prompt engagement with the uncertainty management 
process (Brashers, 2001) to question how worthwhile and meaningful results are in their 
broader health experience. In the earlier case of Matt Fender, who thought he was certain 
to develop Alzheimer’s disease, news of his predisposition was “disturbing but 
manageable,” (Hercher, 2018, para. 11) and his sensemaking process for his results meant 
consulting with a doctor to seek additional, clarifying information. However, for a 
disease that has no known cure or treatment, Fender’s doctor responded with, “What the 
heck do we do about it, once we know, other than create high anxiety?” (Hercher, 2018, 
para. 13). Anxiety was therefore a mediator of uncertainty management in Fender’s case, 
as it is a mediator in “dozens” of other instances when DTCGT reveals a high risk of 
disease. Reported by Sumathi Reddy (2019, para. 11) in the Wall Street Journal, also 
through the example of Alzheimer’s disease, “the stress of knowing” your genetic 
predispositions presents its own consequences for risk management, as consumers have 
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to grapple with what their predisposition means for them and for their family, who might 
inherit the disease risk. The self-managed consumer, in this context, is presented in the 
discourse as one who is subject to the uncertainty and risk management process, having 
to ask themselves just how valuable the information stemming from DTCGT can be for 
their health journey.  
Thus, the articles—especially those from 2017–2018 when consumer disease risk 
tests were first authorized by the FDA—spent much time advocating for doctors and 
genetic counselors to be involved in the testing process and for consumers to confirm 
their results using clinical testing if needed in order to ameliorate uncertainty posed by 
DTCGT. Not only did the articles present these recommendations, but gentech companies 
themselves include the recommendation for medical supervision and additional testing in 
their fine print. However, the acknowledgement was pervasive throughout the dataset that 
although these are the recommendations, most all DTCGT consumers proceed without 
heeding this advice and instead use genetic tests to satisfy their curiosity of the self.   
Datafication: The datafied consumer 
23andMe is among a crop of new services that have arrived to help us mine our 
genetic material for answers to questions we didn’t even know we had. These 
services’ ancestral algorithms are based on estimates and probabilities, not 
certainties, but they nevertheless claim to distill the self into a series of 
appealingly specific data points onto which personal narratives can be written. 
—Hess, The New York Times 
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 Acts of datafication were documented in the articles not only in the way that 
genes are translated into quantifiable records through DTCGT, but in the ways those data 
live on after being characterized. “Datafication” as a code that emerged from the dataset 
was most frequently marked by phrasing that describes how DTCGT takes place: 
The process for customers is simple. A customer spits into a tube and then mails it 
to 23andMe. The company’s lab extracts DNA from the saliva cells and tests it 
with probes that find genetic markers using a special chip for genotyping. In about 
six to eight weeks the company sends the customer an email saying the results are 
in. By logging onto an online account, the customer can see the report and its 
interpretation. (Kolata, 2017a, para. 6) 
 The spitting, sending, and sampling of saliva was noted at least 10 times 
throughout the dataset as the catalyst that enables the genetic testing experience to occur. 
The genetic breakdown that ensues from “a simple saliva sample” can “provide people 
with information” (Kolata, 2017a, para. 1 & 7) or “unlock information in…DNA” 
(Marcus, 2018b, para. 2) that helps consumers understand their health or their relation to 
their family heritage. The very definition of datafication posits the physical body as 
something to be translated into immaterial information—and articles certainly did not fall 
short of referencing the “growing stream” (O’Connor, 2017, para. 5) or the “huge trove 
of genetic data” (Roland, 2019, para. 2) that results from DTCGT. The subsequent 
“genetic portfolio” (Daalder, 2018, para. 2) that users receive from 23andMe or 
AncestryDNA to visualize their results was framed in the dataset as a “roadmap to your 
genealogy and, in some cases, information about what diseases you’re most susceptible 
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to” (Ravenscraft, 2019, para. 1). The “map” analogy was furthered for ancestry genetic 
testing in that 23andMe and AncestryDNA quite literally use a map of the globe to 
display ethnic breakdowns; in a USA Today article describing 23andMe’s 2018 update to 
its genealogy algorithm, author Christina Farr writes, “The update will include 120 new 
regions across the globe. The product will be a lot more interactive, so users can zoom 
into their ancestors’ geographic regions on a map” (Farr, 2018, para. 3–4). The invitation 
to interact with their own data supports the subject position of the datafied consumer—it 
posits consumers as the data points that they then get to interact with in visualizations 
that are easy to comprehend. Genetic data are granted meaning and sensemaking 
capabilities when presented in these visual formats that work to make data all the more 
lively for the datafied consumer. Especially in the instance of ancestry genetic testing, 
where genetic testing results are incorporated into a database accessible by members who 
pay for Ancestry.com subscriptions, genetic data help to elucidate familial relationships 
through the social media side of the company’s website. Members are presented a virtual 
family tree based off their genetic testing results that link directly to social media 
profiles, where they can interact with family members who share an interest in furthering 
their family’s genealogical research. As Krueger (2018, para. 9) writes in The New York 
Times, “The result [of ancestry genetic testing] is a more layered version of what 
happened when Facebook first emerged and out-of-touch family members found one 
another.” In this right, genetic data develop their own social lives akin to the network 
society explained by Levina (2010). Data visualizations that are engaging, visually 
appealing, and easy to comprehend prompt the development of the social networking 
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experience. As social media networks grow, so too does the popularity of AncestryDNA 
and 23andMe as more consumers buy into genetic testing to expand their family trees. 
This notion provides further support that the datafied consumer is one whose data are 
commodities that propel the network society and establish gentech companies at the 
meso-level as being powerful entities that mediate between the state and the consumer 
experience of testing. 
  However, the liveliness of data and the ability to “see” it at all brings with it the 
ramifications of how data are handled, which were referenced abundantly in the dataset. 
A 2019 article from Edward Baig at USA Today framed the process of initiating a 
consumer genetic test as “surrendering” saliva to a gentech firm, rather than “sending” or 
“sampling” saliva, as if taking part in a consumer genetic test is a forced act commanded 
by another (Baig, 2019, para. 1). The article was written in reference to third-party 
sharing of genetic data, which implies that when the datafied consumer “surrenders” their 
saliva, they might also be forfeiting their last chance at genetic privacy and ignorance of 
their genetic underpinnings, i.e., consumers’ notions of who they conceptualize 
themselves as, who they think they are, might be challenged once genetic testing results 
are received.  
 Third-party sharing of data represents the most documented code within 
datafication, counted at least 19 times in the dataset (see Table 1). Two of the more 
commonly referenced third parties where genetic data are shared are that of Promethease 
and GEDmatch, the former which “promises to do a more in-depth analysis for genetic 
mutations that cause disease” (Kolata, 2018, para. 3) and the latter that can “find 
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biological relatives or…construct elaborate family trees” (Murphy, 2018b, para. 2) 
beyond what 23andMe and AncestryDNA can provide. These third parties work through 
expanded reference populations, thanks to “publicly available data” and literature that 
details “gene variants reported to be linked to disease” (Kolata, 2018, para. 30 & 9) to 
send consumers updated reports about disease risk or ancestry periodically over time. 
However, just as 23andMe and Ancestry have their own algorithms for delivering results, 
so too do third-party companies, which adds another instance where data can be 
inaccurate and misinterpreted on the consumer’s behalf. Promethease and GEDmatch 
face even less regulatory scrutiny than AncestryDNA and 23andMe due to their third-
party status, which safeguards them from having to provide “conclusive” and clinically 
validated” results (Kolata, 2018, para. 1 & 22). The implications as such mean that the 
consumer will have to shoulder the worry and frustration that comes from a false-
negative or false-positive result.  
Across the articles on third-party sharing of data is a potential ramification that 
was referenced only three times across the articles under study: that when the third-party 
that obtains access to genetic data is a consumer’s insurance company, the result could be 
an “insurance death spiral” that increases costs for consumers (Kolata, 2017b, para. 17). 
The Obama-era Genetic Information Nondiscrimination Act (GINA) protects consumers 
in the event they have a genetic predisposition for a disease such that employers “cannot 
ask employees to take gene tests and cannot use any such results in employment 
decisions; insurers are not permitted to require gene tests or to use the results in coverage 
decisions” (Kolata, 2017b, para. 11). However, long-term care and life insurers are 
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exempt from GINA and are able to inquire about health status in order to make coverage 
decisions. If patients decide not to report their genetic risks for fear they will be denied 
coverage, premium prices will skyrocket as policyholders get sicker. “Increasing numbers 
of people at low risk might decide the insurance was not worth the rising price. Even 
many at high risk would eventually find the policies unaffordable,” Kolata (2017b, para. 
17) explained. Members of the military, veterans, Native Americans, and small business 
owners with fewer than 15 employees are also not protected by GINA, leaving their 
genetic information subject to insurance discrimination (Genetic Alliance et al., 2010). 
The notion that consumers might conceal their genetic predispositions in the pursuit of 
long-term care insurance is supported by a study done by Dr. Robert C. Green from 
Harvard University, which “found that those who learned they had a gene variant…were 
nearly six times more likely to buy long-term care insurance than those who did not. […] 
Many thought there was no need to tell the insurer why they suddenly wanted the policy” 
(Kolata, 2017b, para. 22–23; Taylor et al., 2010).  
 Finally, third-party sharing of data goes beyond that of gentech DNA databases to 
include the ways that gentech firms share data for their own research gains. Meso-level 
discourse describes how gentech firms have contracted with “[research] companies” 
(Marcus, 2018b, para. 18) and “drug giants” (Roland, 2019, para. 2) to share consumer 
genetic data in an effort to accelerate drug development, conduct research into the genetic 
basis of disease and lifestyle factors, identify candidates for clinical trials, and more. 
Several articles in the sample served to describe what consumers should know before 
they submit their data for a DTCGT by reiterating that “customers are free to opt out of 
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the research option at any time or delete their data” (Suppe, 2018, para. 27) and they 
should also “read the company’s privacy policy” (Ravenscraft, 2019, para. 6) in order to 
develop informed consent. Contained within those privacy policies are 23andMe and 
Ancestry’s claims that all consumer data shared with another entity is “de-identified and 
aggregated” (Suppe, 2018, para. 13; Ravenscraft, 2019, para. 13), meaning a consumer’s 
name and personal information are stripped from their genetic data, and those data are 
then combined with data from the millions of other consumers who have submitted to 
DTCGT in an effort to maintain a consumer’s privacy to third-party companies. 
However, glossed over in policies on de-identification and aggregation is the latent 
understanding that all DNA can be traced back to a consumer, no matter any attempt to 
anonymize it, because DNA is a personal map and genetic fingerprint that is unique to 
each person. 
This review of the third parties mentioned in the dataset, i.e. Promethease, 
GEDmatch, health insurance providers, and biotechnology and pharmaceutical 
companies, serves to position the datafied consumer in regard to the entities that hold 
power over consumers’ personal genetic data. When juxtaposed beside companies that 
collect, mine, and disseminate genetic data, the individual testing consumer can be 
viewed as the “data poor” who is in opposition to the “data rich,” which implies a certain 
level of value that consumers’ genetic data must hold if testing companies are so 
motivated and eager to maintain and advance the genetic testing experience (Ruckenstein 
and Schull, 2017). The datafied consumer is subjected as a form of biocapital for 
companies to extract profitable information from, eluding to Rose’s (2007) concept of the 
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bioeconomy and neoliberal principles of a market that creates biologically informed, 
productive citizens. However, a caveat of the biological citizen, referenced in literature 
and in this dataset, is the potential for data to become tracked and monitored by those 
entities who store and share genetic data. 
Consumer privacy thus marked another code found in the dataset; in fact, it was 
the second-most frequently documented code of all the articles read (see Table 1). How 
gentech companies are seeking to protect consumer data represents possibly the greatest 
challenge to DTCGT and is made more difficult by the fact that “it’s impossible to fully 
anonymize such intrinsically personal data like DNA” (Suppe, 2018, para. 13). As 
mentioned, consumer companies rely on deidentified, aggregate data which claim to 
make DNA untraceable “back to the individual” (Suppe, 2018, para. 11); however, 
researchers have shown that it is possible to identify testing consumers by using 
predictive analytics to ascertain familial relationships through mining genetic data 
(Erlich, Shor, Pe’er & Carmi, 2018; Kim, Edge, Algee-Hewitt, Li & Rosenberg, 2018). 
Further, Ravenscraft (2019, para. 2 & 15) highlighted that genetic data “can become 
difficult to track” and are “difficult or impossible to delete” once they are shared with 
gentech companies. Suppe (2018, para. 17) also went on to present the divide between 
consumers’ opinions on privacy concerns by framing those who are “supporters of 
research” and have therefore consented to sharing their data to inform medical knowledge 
against those like 38-year-old testing consumer Drew Olanoff, who closed his 23andMe 
and “asked to have his data deleted” because “he never opted in to donate his data for 
research in the first place” (para. 31). Additionally, authors Marcus (2018c, para. 21) and 
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Murphy (2018a, para. 2) presented the popularity of DTCGT as a threat to consumer 
genetic privacy because “databases are growing so rapidly” that “already, 60 percent of 
Americans of Northern European descent…can be identified through such databases 
whether or not they’ve joined one themselves.” This possibility makes it even more 
difficult “for individuals to retain any anonymity” (Murphy, 2018a, para. 2) in their 
testing experience and calls for “‘a re-evaluation of the status quo’ when it comes to 
genetic privacy, especially in the U.S., where genetic testing is increasingly accessible” 
(Marcus, 2018c, para. 22).  
These codes—of overt instances of datafication, third-party sharing of data, 
insurance discrimination, and privacy concerns—are grouped together because they 
represent illustrations of how the physical become the datafied and are then mined for 
further information. The articles highlight that genetic data are valuable sources of 
information that gentech companies can (and do) use to prop up their research agendas, 
therefore increasing opportunities for market collaboration that increases the monetary 
value of these companies. Consumer data were not presented as a simple exchange 
between two entities; rather, data live on beyond the gentech firm’s laboratories and take 
on new purposes as they are shared. From a technological sense, data are presented as the 
crux upon which predictive analytics function to mine data for information; without data, 
algorithms used by gentech firms to draw connections between genes would not have a 
purpose. Thus, a latent feature of the datafication theme in these articles is that third 
parties will continue to develop new ways to use and understand genetic data; new 
companies will continue to establish with the sole purpose of developing novel avenues 
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for studying consumer-provided data. Consumers, being the sources of information, are 
again the data points in the scenario. With growing interest from the biotechnology 
industry in the use of those data points, consumers as generators of bio-value, searchable 
by “the state” i.e., governments and private industry, is the final important theme of this 
study.   
Power: The valuable consumer 
The pitch for home DNA testing could not be more succinct: know thyself, for a 
fee.  
—Herrman, The New York Times 
  Referring back to LeGreco and Tracy’s discourse tracing, government agencies 
and law enforcement were identified in this study as the macro-level entities that create 
and participate in the web of scientific-technological-economic power relationships 
surrounding DTCGT. This web is nuanced; it includes not only the regulations set forth 
by the government that permit the sale of consumer genetic tests, but the ways that 
government can benefit and extract value from databases of genetic data. As data live on 
and become repurposed by third-parties, opportunities arise for powerful entities to use 
genetic data to reinforce longstanding social divisions, to interfere in the personal privacy 
of citizens, and to fuel the continuation of individuals as productive citizens who serve 
the overall well-being of the state and corporate interest. Power is nuanced because it is 
often implicitly wielded, and the articles studied did not fall short of exemplifying that. 
Codes relevant to the theme of power and biocapital were recorded more often than the 
other codes in this study (see Table 1). 
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 The conversations surrounding power over genetic data were established in the 
dataset beginning in 2018 when the “Golden State Killer”, Joseph James DeAngelo, was 
apprehended by law enforcement using the newfound method of genetic genealogy and 
familial DNA searching. The method allowed law enforcement to reverse-engineer 
DeAngelo’s family tree by first taking DeAngelo’s DNA collected from a crime scene 
and converting it into a digitized format suitable for GEDmatch. Once uploaded, 
GEDmatch’s algorithm connected law enforcement to 10-20 of DeAngelo’s distant 
cousins. Genealogists traced those cousins back to a common ancestor—DeAngelo’s 
great-great-great grandparents—and then laboriously traced every branch of those 
grandparents’ offspring until they had 25 distinct family trees and 1,000 possible 
suspects. After narrowing down the search to family with ties to Sacramento in the 1970-
80s, only two suspects were left: DeAngelo and one other, who was later eliminated 
through a relative’s DNA analysis. DeAngelo was apprehended after law enforcement 
tested his DNA—gathered from trash he disposed of at his house—against DNA from the 
1980s crime scene (Jouvenal, 2018; McMahon & Harris, 2019).   
 Law enforcement’s use of DNA databases is nothing new; state law enforcement 
has their own DNA database—the Combined DNA Index System (CODIS)—which 
aggregates genetic profiles of any person convicted of certain crimes or DNA profiles 
found at crime scenes. What makes the Golden State Killer case different was the use of 
the public, open sourced, consumer-provided database of GEDmatch, because, “while 
safeguards exist to make sure the information uncovered from criminal databases isn’t 
misused or disclosed improperly by police, none of those regulations exist for 
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commercial databases” (Yancey-Bragg, 2019, para. 8). The overarching, deeply ethical 
concern brought about by the Golden State Killer case was that very first step in tracing 
DeAngelo’s family tree: that law enforcement took a DNA sample from a crime scene 
and uploaded it to GEDmatch, technically, as a fake identity. When doing so, detectives 
on the case certified “that the DNA was their own or belonged to someone for whom they 
were legal guardians, or that they had ‘obtained authorization’ to upload the sample” 
(Kolata & Murphy, 2018, para. 11).  
Besides a glaring violation of the site’s intent, the case raises a whole set of 
ethical questions that were well characterized in the articles studied. First, the case of the 
Golden State Killer—a serial rapist and murderer—provided one of the first high-profile 
investigations using genetic genealogy, and police have since used the method to convict 
other crimes, such as assault and battery. This questions the limit on the types of crimes 
investigated through genetic genealogy: “If the police felt free to use it in an assault case, 
why not shoplifting, trespassing or littering?” (Joh, 2019, para. 8). And just because 
police can use DNA technology in this way, should they be able to? Secondly, the case 
tiptoes around informed consent for DTCGT consumers. As one USA Today article 
characterized, consumers who submit their DNA to GEDmatch might as well consider 
themselves “genetic informants” on their relatives, given genetic genealogy’s ability to 
trace family trees (May, 2018). While the consumer themselves might consent to use 
their genetic profile in a criminal investigation, their relatives have not, and there is no 
way for those relatives to opt out of the method. “You may never commit a crime. But 
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how should you feel if your DNA was used to locate a distant relative who did?” (Kolata 
& Murphy, 2018, para. 19). 
Taken together, the concept of individual genetic privacy seems all but abandoned 
in police’s unregulated use of public genealogy databases. Power is taken very literally in 
this sense: “there aren’t strong privacy laws to keep police from trolling ancestry site 
databases” (May, 2018, para. 14) and in turn, consumers who have participated in 
GEDmatch and other public genealogy databases are putting “really revealing genetic 
information...in the hands of law enforcement with no restrictions whatsoever” (Yancey-
Bragg, 2019, para. 19). Without court orders and established precedent on how to handle 
genetic and digital identities, there is little consumers can do to protect their data, and 
thus “the limits on Americans’ genetic privacy are being fashioned by private entities” 
(Joh, 2019, para. 10). This unregulated point of the consumer testing experience relates 
back to the biopolitical concept of dataveillance in which interested parties seek to track 
consumers in order to monitor and modulate consumer behavior. In the case of law 
enforcement use, data-tracking helps delineate between the criminal and the innocent and 
represents a practice that macro-level governing entities can employ to control the micro-
level consumer.  
 Genetic genealogy presents an entry point to an entirely different reality of 
DTCGT, that of minority underrepresentation and race classification. Minorities are 
“disproportionately represented in state databases” like CODIS and could be targeted by 
law enforcement through the search of public databases (Hernandez, Kanno-Youngs, & 
Elinson, 2018, para. 11). However, what law enforcement will find in the search of those 
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public databases is likely an underrepresentation of minority genetic profiles. Five 
articles studied in the dataset expressly discussed “the need for more genetic diversity” in 
DTCGT as more people from minority backgrounds seek to participate in commercial 
testing that is presently primarily comprised of DNA profiles of European ancestry 
(Marcus, 2018a, para. 4). A history of scientific racism once disincentivized minority 
populations from participating in genetic research out of “concern about potential misuse 
of DNA results and mistrust of health research” (Marcus, 2018a, para. 5). Marcus 
referenced the “past wounds” that genetic research reopens for minority populations, 
noting that the history of unethical studies in underrepresented groups requires more 
dedication now to reassure minorities that it is safe to participate in research and that their 
data will be cared for properly. The benefit of participating, for gentech companies, 
means that more tests will be sold and more profit is garnered; for minorities, more 
testing means more accurate results as more minorities are added to the companies’ 
reference datasets.  
Yet, as previously described, invitations for law enforcement to surveil minorities 
as possible criminal suspects will become more frequent as more profiles are added in the 
public genealogy sphere. Further, as more consumers buy into DTCGT, the attempt of 
gentech companies to characterize the social conception of race will become more 
prominent. At least three articles studied directly questioned whether or not genetic tests 
for ancestry are “meaningful” or “instructive,” because “genetic data is technical and 
identity is social” (Kolata, 2017c, para. 24; Nelson, 2018, para. 2). At the core of it, 
ancestry tests are misinterpreting the ways that we as a society discourse about race and 
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are irresponsibly erring onto and past scientific controversies that claimed race as a 
genetically determined feature. Genetic reductionism, or the understanding that genes 
alone are enough to describe human behavior and traits without consideration for 
environmental or societal influences, is what occurs when “race” and “genes” are 
conflated with one another (Carter, 2007). Articles in the dataset—especially those 
written by Kaplan (2019), Zimmer (2018b), Hess (2018) and Kolata (2017c) from The 
New York Times—did well to note that at the deepest, most scientific breakdown of who 
we are, all humans are comprised of the exact same 99.9% of DNA. What sets us apart is 
a negligible fraction of genetics that can be traced back to our countries of origin 
thousands of years ago. This definition represents ethnicity, or the geography of where 
we came from, and while ancestry genetic testing returns results that claim to dictate 
ethnicity, “public airings of DNA results often read as an attempt to transcend race by 
revealing hidden, scientific-seeming insights that expose our ‘true’ origins” (Hess, 2018, 
para. 8). The ensuing consequence of these tests, noted in the articles, is a society of 
consumers who are sure of themselves and their ancestral roots, but are more easily 
divided when race is politicized in the news headlines. Power/knowledge is therefore 
exercised over genetic testing consumers who have ascribed their ethnicities to be their 
identities to create an us vs. them mentality when it best serves the state’s agenda. And, 
from a racialized vantage point, genetic testing strengthens the deployment of race 
categories by biologizing the conception of race to a purely genetic component that 
gentech firms embolden in their formations of genetic knowledge. The danger in equating 
ethnicity and race as the same, or race in a geneticized basis, is the reemergence of a 
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“new truth about human identity” that errs on a reemergence of scientific racism (Carter, 
2007).   
Additionally, paying for service represents another code documented in the 
dataset that establishes the power and biocapital theme. This code was noted in the study 
any time an article mentioned the financial costs associated with DTCGT: On an 
everyday basis, “many [genetic tests] are available for under $100, making genetic tests 
increasingly affordable for greater numbers of consumers” (Marcus, 2018b, para. 3) and 
especially around the holidays when “some [tests] are going for as low as $49” (Pitzl, 
2017, para. 13). The monetization of the genetic testing experience is inherent to the 
power + biocapital theme, as it reinforces the concept of the bioeconomy. Pay-for-service 
models are what bolster gentech companies like 23andMe and AncestryDNA in 
consumer markets; money is what wields prominence and allows companies to develop 
partnerships that establish influence. A 2019 article from The Wall Street Journal 
exemplified this relationship: “23andMe signed a $300 million agreement last year giving 
the pharmaceutical company GlaxoSmithKline rights to use genetic data for drug 
discovery” and it was that “drug development pipeline” that CEO Anne Wojcicki hoped 
would “power” 23andMe in its 2019 profits (Winkler & Marcus, 2019, para.10 & 1). The 
partnerships created and the products that stem from those partnerships are what gentech 
companies use to incentivize consumers’ continual engagement with their companies; the 
offerings represent “a broader, growing marketing strategy” that intends to “tap into the 
idea that DNA is deterministic, that genetic differences are meaningful” (Herrman, 2018, 
para. 13).  
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For example, Herrman writes about AncestryDNA’s 2018 partnership with the 
music streaming app Spotify to create playlist that supposedly delivers the “sound of your 
DNA”; songs are chosen for the playlists based on the top 5 regions of the world where a 
consumer’s DNA can be traced. Attributing a sonic ability to the very biological property 
of DNA represents a marketing attempt by gentech firms to make genetic testing into a 
compelling, personalized form of entertainment; but more critically, it represents a very 
clear example of how “everything in the world is getting biologicalized” (Herrman, 2018, 
para. 9). Music is inherent to our cultural identities, and it exists as a form of expression 
of our innermost thoughts and feelings. We make sense of ourselves often by connecting 
with the lyrics of songs, and we connect with others through instances when music is a 
shared experience. To compile the results of an ancestry genetic test into that of a Spotify 
playlist “provides a free and easily accessible way to experience the limits of DNA 
testing in the pursuit of self-knowledge” (Herrman, 2018, para. 17). For the subject of the 
datafied consumer, Spotify-AncestryDNA playlists are like souvenirs of the genetic 
testing experience that relate back data’s liveliness and sensemaking capabilities. From 
the vantage point of the valuable consumer, playlists also represent how AncestryDNA 
will “trade in the prestige of genomic science…in order to sell more stuff” (Herrman, 
2018, para. 13). Consumers’ data, their money, and their human DNA are situated in the 
genetic testing experience as the biocapital that gentech companies leverage to strengthen 
their market positions through attractive products and offerings that compel consumers. 
The final code contained within the theme of power and biocapital is that of 
government involvement in the DTCGT experience. This code was characterized by the 
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ways that articles under study referenced government entities, e.g., the military, IRS, the 
FDA, and law enforcement, and the regulations and/or policies they instate to wield 
control over 23andMe and AncestryDNA. This code was established from the very first 
article studied, which highlighted the FDA’s 2017 decision to “for the first time…allow a 
company to sell genetic tests for disease risk directly to consumers” (Kolata, 2017a, para. 
1). The decision represented “a turnaround for the agency, which had imposed a 
moratorium in 2013 on disease tests sold by the company 23andMe” (Kolata, 2017a, 
para. 2). The moratorium referenced had ordered 23andMe to stop the sale of their 
DTCGT until the technology had received marketing authorization from the FDA. At the 
time, the FDA considered DTCGT to be an unclassified medical device, and they had 
questions about the “analytical and clinical validity” of the tests. For the four-year period 
from 2013-2017, the FDA and 23andMe worked in cohort on the regulatory premarket 
review process until the FDA was satisfied with the data provided by 23andMe and 
deemed that the tests “can be used safely without professional supervision” (Yim and 
Chung, 2014). In 2017, as news of FDA approval made its way throughout media, The 
Wall Street Journal picked up the story and announced the FDA’s decision as “a turning 
point in the democratization of personalized medicine” (Huber & Howard, 2017, para. 1).  
A year later, in March of 2018, the FDA extended its approval of 23andMe to 
offer home tests for three breast cancer mutations—a position that just one year earlier, 
the FDA said they would not allow as “diagnostic tests [such as a genetic test for BRCA] 
are often used as the sole basis for major treatment decisions” for which a medical 
provider was required to initiate with a patient (U.S. Food and Drug Administration, 
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2017). Although a switch in positions, The Wall Street Journal reported that because of 
the FDA’s rigorous review of 23andMe from 2014-2017, it was able to “more quickly 
approve the cancer risk tests” because it had “assessed the scientific precision of 
23andMe genetic work in general” and deemed it to be “safe and effective” (Burton, 
2018, para. 6 & 12). As Burton went on to describe, the presidential election of 2016 was 
also a significant catalyst to the FDA’s decision to allow 23andMe limited medical 
testing, given the shifting regulatory agendas between Presidents Obama and Trump: 
“Under the Obama administration, the FDA had focused its concern on lab-test accuracy 
and safety…The emphasis has shifted now toward simplified approvals of innovative 
tests. After President Donald Trump’s election, the Obama FDA backed off from lab-test 
regulatory plans,” which therefore spurred 23andMe’s FDA approval as it exists today 
(Burton, 2018, para. 14–15).  
The transition between presidents demonstrates the power of changing leadership 
and policy agendas, as well as the power that both the executive and legislative branches 
of government hold over regulatory entities who are involved in DTCGT policymaking. 
This was furthered in the dataset by mentions of the Federal Trade Commission, which 
“has the ability to police unfair and deceptive business practices across all industries” in 
the event that consumers question “how to protect and delete [their] data” if they suspect 
a gentech company has misused or improperly shared with third-parties (Ravenscraft, 
2019, para. 5 & 1). And, the 2019 decision by the IRS tax agency to “greenlight tax 
breaks for buyers of 23andMe genetic tests” represents again how consumers are 
provided with incentives to engage with the consumer genetic testing industry (Rubin & 
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Marcus, 2019). The IRS ruling determined that the “health portion of 23andMe’s test is 
medical care for tax purposes” meaning that “people with tax-advantaged flexible 
spending accounts or health-savings accounts…can use that money to purchase the kits” 
(Rubin & Marcus, 2019, para. 5 & 7).  
 These examples of government involvement in the testing experience are 
significant to the subject position of the valuable consumer because they situate the 
consumer as a source of free, clinical labor for the powerful entities that oversee DTCGT. 
23andMe and Ancestry rely on consumers to purchase their testing so that they can 
source more genetic data to conduct research and broker research partnerships. 
Governing entities, too, have a vested interest in privatized technologies so that they can 
get more for less; partnering with private industry allows government to delegate their 
research agendas while lessening the burden of research costs on their budgets. For this 
purpose, consumers and the genetic data they provide stand as the commodities of 
exchange that ensure the consumer testing experience and enable these entities to 
progress. Technically, consumers are research participants who contribute to the 
advancement of genetic knowledge, though they are not credited for their contributions 
and they have to pay to participate in the research experience—two qualities that 
distinguish privatized science from traditional tenets of academic research. 
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CHAPTER FOUR 
DISCUSSION 
 
The intent of this study was to examine the discourses that are present in the news 
media on DTCGT, with special attention paid to the ways that news articles engage with 
issues of ethics in consumer genetic testing technology. The findings show that DTCGT 
is, indeed, the “unregulated wild west” (Yancey-Bragg, 2019) due in part to the novelty 
of consumer testing technology, but also due to the privatized nature of testing that 
thrives on corporate profits. DTCGT is riddled with unique scenarios that push the 
bounds of self-curiosity in order to deepen consumers’ understandings of themselves, 
their health, and their ancestral roots, but that curiosity does not come without equally as 
many scenarios that cause me to pause and ask how gentech companies can support 
consumers’ genetic journeys while also helping to safeguard the testing experience.  
 When I first set out to complete this study, I did not know what themes and 
discourses I would find in the articles studied. Being a former student of genetics, I was 
personally concerned about the ramifications of DTCGT, but even I did not expect for 
these ramifications to be highlighted as frequently as they were in the sample studied. 
Ultimately, RQ1 (what discourses are present?) and RQ2 (to what extent are ethics 
represented?) reaffirm one another, in that, discourses on DTCGT in news media are 
defined by the social, political, and technological constructs that precede (and become 
emboldened by) genetic testing technology. When we ask whether medical professionals 
should be included in the consumer testing experience; whether tests are “clinically and 
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analytically valid”; whether the risk of knowing our genetic predispositions is worth the 
ensuing anxiety; whether data should be shared with other for-profit companies; and so 
on, we are engaging in critical dialogue that attributes meaning to genetics as a science 
and DNA as the carrier of information that dictates how humanity evolves. For consumer 
genomics companies to continue operating without engaging in these discursive practices 
would be a disservice to the history of geneticists and scientists who first characterized 
DNA and its tangential biological mechanisms. It would also be a disservice to the self-
managing, datafied, valuable consumer at the center of the testing experience.  
 Therefore, an obvious outcome to this study would be a call for regulation on 
personal genomics companies to address issues of consumer privacy, law enforcement 
use, third-party sharing of data, and others highlighted here. The reality is that 23andMe 
and AncestryDNA function in a novel, loosely defined market that creates regulatory 
challenges. Is DTCGT a wellness product? A medical device? A technological 
innovation? The FDA’s premarket review of 23andMe treats DTCGT as a medical device 
because “it is intended for use ‘in the diagnosis of disease or other conditions or in the 
cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure 
or function of the body’” (Yim & Chung, 2014). But, what about ancestry genetic testing 
that serves the purpose of recreation and entertainment or of quelling the consumer’s 
interest in non-medical properties of their DNA? There is a great need for clarification on 
how this technology should be defined if any policy progress is to be made on issues of 
ethics. Although I will be the first in line to advocate for greater transparency and 
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protections on what testing is and how data are handled, until DTCGT can be defined 
among stakeholders, its regulatory pathway remains unclear.   
 Still, for all the ethical lines of inquiry that this study takes, there is a tantamount 
acknowledgement to draw from the data: that is, DTCGT has placed genetics on the 
agenda, in public life and in consumers’ personal lives. The explosion of the personal 
genomics industry in the late 2010s garnered interest from millions of people across the 
world about their genetic selves: the health that they inherited from their families and the 
geographic locations from which those families began. While the accuracy of DTCGT is 
contested—because of proprietary algorithms and genome panels that provide only a 
snapshot of all the possible genetic markers for a trait—the benefit of DTCGT for 
genomic literacy is something to be celebrated. Never before have humans been so 
engaged with the science of genetics—how traits are passed down through generations, 
how mutations arise, or how DNA can be traced geographically—for no reason other 
than sheer interest. It should be an endeavor of private testing firms to harness interest 
into campaigns for genomic literacy awareness that not only make their practices more 
transparent to the public but continue to persuade and educate consumers on genetic 
sciences.  
Theoretical Contributions and Implications 
The framing of DTCGT in the articles studied helps to garner insights that further 
the theories and frameworks outlined in this study: those of risk and uncertainty, 
datafication and the “quantified self”, and governmentality and biopolitics. As a 
technology premised on testing for genetic predispositions to disease, DTCGT is riddled 
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with contexts that create uncertainty for the consumer. Brashers (2001) theorized 
uncertainty as a multilayered, interconnected, and temporal experience that prompts 
various considerations from the person at the center of the uncertain outcome. The 
articles studied nodded to this notion, as DTCGT elicits questions from the consumer 
about genetic risk, accuracy of results, and informed consent throughout the testing 
experience and, in some cases, even before testing has been ordered. In the example of 
health genetic testing, consumers are charged with considering whether it is beneficial to 
their well-being for them to know about their genetic predispositions in the first place or 
whether ignorance really is bliss and the choice to remain uninformed will give them 
greater peace of mind. Yet, if a consumer does proceed with testing, results might conjure 
up feelings of anxiety or worry for themselves as the at-risk individual or for their loved 
ones who might inherit the same predispositions. The process of receiving risk 
information, appraising the results to gauge their meaning and significance, and deciding 
a planned behavior to negotiate those uncertainties affirms Brashers (2001), as well as 
Affifi and Weiner’s (2004) theory of motivated information management. The 
understanding that DTCGT is an uncertain experience should only heighten calls for 
private gentech firms to be more transparent and instructive in how they analyze and 
convey genetic risk information.  
Additionally, this study supports theories that genetic risk is socially constructed 
and that it perpetuates society’s divide between the chronically ill and the worried well. 
Consumers that are drawn to genetic testing for health reasons are participating in the 
present model of healthcare that prompts the continual, constant search for disease and 
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any symptoms that might cause disease later on. If we are always on the lookout for a 
danger to our health, there is a greater likelihood that we will find something to worry 
about—and risk assessments provided by DTCGT are no exception. Before DTCGT was 
available to consumers, genetic testing as a health mediator was mainly reserved for 
conditions and symptoms that stumped medical professionals. Genetic testing was not 
regular procedure; but now, more than 26 million consumers have received risk 
information from private gentech firms, which places “risk” in a more salient context. 
The focused emphasis on genetic risk in light of DTCGT stands as an example of how 
advancing technologies—and societal discourses about those technologies—can amplify 
the significance granted to “risk” in health decision making, which supports its social 
construction. Moving forward, there is a need for scholars to theorize realistic ways to 
help consumers process genetic risk information, given that DTCGT is present and 
ongoing. Arguing for greater methods of uncertainty reduction or information seeking 
can be problematic because more information might be overwhelming, and excessive 
explanations of risk could snowball into heightened feelings of anxiety. As such, it is 
important that risk be conveyed responsibly at the first instance when a consumer 
receives their genetic testing results, so as to quell any negative emotions after the fact.  
 The consequences of the datafied consumer represent another implication for 
theories that engage in the liveliness of data (Lupton, 2017), the network society (Levina, 
2010), and acts of dataveillance (Van Dijck, 2014). Articles here presented clear 
descriptions of the transformation of saliva into genetic data. The possibilities of what 
those data can reveal—in research, as things to be experienced recreationally, and as 
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commodities that further corporate profits—are possibilities that that preceded critical 
thought on how genetic data should be handled. In the future, theories would benefit from 
inquiry that imagines datafication as a central precept of the DTCGT experience and 
works to explicate the meanings of data in all the spheres they end up in, e.g. social 
networking websites, law enforcement investigations, and third parties like Promethease, 
Spotify, and GEDmatch. There is a need to understand how consumers derive their 
identities at least in part from their understandings of their genetic data, and how 
identities are further challenged when genetic testing results do not align with their 
conceptions of self. And, there is especially a need to lessen the possibility of 
surveillance of genetic data for nefarious purposes by powerful entities.  
Finally, to the extent that the articles positioned DTCGT as a newfound tool for 
monitoring health, this study engages in biopolitical understandings of DTCGT as a form 
of governmentality. Neoliberal extensions of Foucault’s (2010) work on governmentality 
demonstrate that individuals must be in pursuit of healthy bodies in order to maintain 
moral order within a society. As a topic described in the articles, DTCGT was framed as 
a technology of the self that consumers employ to attain healthy status by adjusting their 
behaviors in response to testing results. Yet, to what degree consumers actually make 
those behavior modifications was not clearly presented in the articles and thus elicits 
further inquiry. Relating back to the uncertainty management process, consumers might 
choose not to ascribe meaning to testing results if risks are mild to moderate; therefore, 
the extent of the self-managed consumer depends on a construction of risk that is too 
dangerous not to ignore. The threshold for ascribing action to testing results could further 
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resolve the concept of the biological citizen in DTCGT. Additionally, the lack of 
minority representation in consumer genetic databases signals to a disconnect between 
the state and its minority community. Scholars would do well to focus more attention on 
how lower-income and culturally marginalized individuals are affected by a history that 
has excluded them from scientific research—one that disproportionately affects them 
now when law enforcement gets involved in work with genetic testing. Finally, the power 
asymmetry denoted here between macro governing bodies, meso corporate testing firms, 
and micro-level consumers is a relationship that cannot be diminished as DTCGT 
advances in the coming years. Relating back to Foucault’s power/knowledge concept, the 
discourses contained in this study do more than explicate the varying nuances of 
DTCGT; they also serve as examples of how power can be distilled hierarchically and 
how, in the establishment of consumer genetic testing firms, knowledge can be gained 
from entities that hold power. AncestryDNA and 23andMe have created a baseline for 
knowledge of genetic traits that millions of people have encountered for the first time 
through the establishment of DTCGT. The charts, graphs, and interactive maps provided 
by these companies to display their results helps consumers to understand how DNA 
translates into diseases and ancestral relationships; the companies have, at once, analyzed 
very personal information given freely by testing consumers and also repurposed that 
information as a field of knowledge. For Foucault, power/knowledge is an inseparable 
couplet because power and knowledge reinforce each other in continually developing 
constructs, of which, DTCGT is one.  
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Likewise, power/knowledge and the historical and cultural foundations on which 
DTCGT is built cannot be separated from the conversations had about genetic testing. 
The discourses studied in this thesis are productive not only because they highlight the 
varying ramifications of DTCGT that require careful thought and consideration, but 
because they highlight how powerful entities can foster qualities of self-management and 
control in the pursuit of healthy lives and citizens. Discursive practices help to shape the 
subject of the genetic testing consumer not as passive objects of biopower, but as 
consumers who have wielded knowledge at their fingertips to make informed choices for 
their genetic health. There is an agency to the genetic testing consumer that is 
underscored by the discourses on DTCGT. The marketability of health will only continue 
to develop as technology advances; thus, emphasis must be given to narrow the divide 
between the data rich and the data poor to ensure more transparent discursive practices.  
Limitations 
 This study sought to investigate two research questions that aimed to capture both 
the discourses and ethical issues of DTCGT that are present in news media. While I 
believe this study achieved what it set out to do, it is not without its limitations or areas 
for improvement. First, this study was narrowed down to news media from just three 
sources, The New York Times, The Wall Street Journal, and USA Today. While I certainly 
feel as though I reached theoretical saturation in the 50 articles I examined, this study 
excludes a number of other possible news sources that could have expanded the topic of 
DTCGT even further. As an entrance to understanding DTCGT, I believe the three 
sources chosen served their purpose and provided a comprehensive sampling of the 
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varying issues of ethics that stem from consumer testing technology; however, other 
accounts provided by technology and popular news media, podcasts, documentaries and 
more could work to further triangulate and crystallize the data provided. Additionally, the 
coding process employed here presents another possible limitation to this work. I used the 
constant comparative method to identify the themes outlined here, but these themes only 
tell part of the story of DTCGT. In line with the tenor of qualitative work, this study 
describes only the themes that emerged to me as the researcher; others who review these 
news articles might capture other features from the data.  
Future Directions 
 As evidenced by the limitations, this study serves as just one way to engage with 
data on DTCGT. In my work, I have now completed an interview study with genetic 
testing consumers to gauge their motivations and understandings of testing risks, as well 
as the present discourse analysis to better capture what those risks and ethical issues of 
testing are. An interesting follow-up to this study could shift the testing conversation to 
other subjects involved in the personal genomics industry, such as the medical 
professionals and genetic counselors who help consumers interpret testing results or the 
policymakers that set the regulations on DTCGT. Participant interviews with genetic 
counselors could illuminate how medical professionals help their patients make sense of 
consumer genetic data, whereas a content analysis of policy briefs, governmental press 
releases, and legislative rulings could highlight the varying perspectives and 
considerations that policymakers include when instating regulations on the testing 
industry.   
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 Furthermore, the more concerning outcome of this present study are the findings 
on consumer genetic privacy and third-party sharing of genetic data. More work needs to 
be done by ethicists, law scholars, geneticists, and social scientists to determine 
recommendations for policymakers and corporate entities in order to protect consumer 
data once it is shared with a gentech company. De-identification and aggregation of 
genetic data is not enough; allowing police unregulated reign over public genealogy 
databases is not okay; contributing consumer genetic data to a greedy pharmaceutical 
industry is unprincipled; discriminating against the genetically at-risk through insurance 
coverage is unacceptable—and more studies are needed to help shape the course of 
DTCGT and reel in these concerns in the future.  
 Finally, at the outset of this thesis project, the COVID-19 viral pandemic 
emerged, and scientists across the globe responded by opening their labs and 
transitioning their research agendas to studying the coronavirus’ transmissibility, biology, 
and epidemiology. 23andMe and AncestryDNA have joined in on COVID-19 research by 
offering to analyze consumers’ DNA for genetic differences that determine why some 
COVID patients get sicker than others (Robbins, 2020). The two private firms are 
seeking to assemble a vast trove of study participants in order to contribute to a 
worldwide genome-wide association study of COVID-19 to search for genetic markers 
that might be key in treating the virus or developing its vaccine. Given that 23andMe and 
AncestryDNA represent the corporate arm of a broader scientific community of research 
hospitals and academic labs, their participation in COVID-19 research presents a 
fascinating line of inquiry for future studies to addresses. Namely, the assemblage of 
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relationships between privatized science, medical settings, academia, and government 
organizations demonstrates a powerful moment in scientific discovery when research 
agendas merged, and scientists worked in cohort to resolve an emergent threat to public 
health. Examining the impact of DTCGT in how COVID-19 research progresses could 
deliver insights into how necessary (or not) private gentech firms are to the advancement 
of science.  
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CONCLUSION 
 DTCGT has emerged over the past 5-10 years as a “technology of the self” that 
consumers seek to deepen their genetic self-knowledge. The ability of consumers to 
submit saliva samples to private gentech firms for analysis into their genetic makeup 
represents a modern instance of datafication in the conversion of DNA to genetic data. As 
genetic data are analyzed, shared, and repurposed in the consumer testing environment, 
there exists opportunities for powerful entities to derive value from those data for uses in 
drug development, disease research, law enforcement investigations, and the creation of 
products that enhance the consumer testing experience. 23andMe and AncestryDNA 
represent two of the fastest growing private gentech companies that have established the 
personal genomics industry through tests that characterize disease risk and genetic 
genealogy. Using a Foucauldian discourse analysis of news articles about 23andMe and 
AncestryDNA, this study demonstrated that genetic testing consumers seek to develop 
their genetic knowledge through neoliberal perspectives that position consumers as 
individually responsible for managing and understanding their genetic outcomes. To the 
consumer, genetic data are viewed as a sources of information, but to private gentech 
firms and government entities, data are forms of biocapital that sustain a bioeconomy, of 
which, consumers form the foundation. The advent of the consumer genetic test 
highlights the need for greater studies into the communication of genetic risk and 
uncertainty, as well as policy work that articulates the extent of consumer genetic privacy 
and third-party sharing of genetic data.  
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APPENDIX 
Constant Comparative Codes and Themes 
 
Broader Theme Code Prevalence 
Biocitizenship 
Lack of medical supervision 19 
Accuracy of tests 17 
Risks and uncertainties about testing or 
disease 20 
Datafication 
Datafication of genes 13 
Third-party sharing of genetic data 19 
Life insurance / long-term care 
discrimination 5 
Privacy concerns 28 
Power + Biocapital 
Law enforcement use 15 
Minority underrepresentation / race 16 
Paying for service 11 
Government involvement 36 
Table 1. The initial round of open coding generated the codes denoted in column 2 and 
their prevalence, i.e., the number of times the codes appeared across 50 articles, in 
column 3. Broader themes in column 1 represent how codes were grouped in the second 
round of coding.  
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